CLINICAL STUDY PROTOCOL
Study Title: A Phase 2, Open -Label, Multicenter, Mu lti-cohort Study to 
Investigate the Safety  and Efficacy of Ledipasvir/Sofosbuvir 
Fixed Dose Combination in Adolescents and Children with 
Chronic HCV -Infection
Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive 
Foster City , CA 94404, USA
IND No.:
EudraCT Number:115268
TBD
Indication: Hepatitis C Virus I nfection 
Protocol ID: GS-US-337-1116
Gilead Sciences Medical 
Monitor:Name: Luisa Stamm, MD, PhD
Telephone:
Mobile:
Fax:
E
-mail:
Protocol Version/Date: Original: 10 July2014
CONFIDENTIALITY STATEMENT
The information contained in this document, particularly unpublished data, is the property or under control of 
Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or 
consultant, for review by y ou, your staff, and an applicable Institutional Review Board or Independent Ethics 
Committee. The information is only to be used by you in connection with authorized clinical studies of the 
investigational drug described in the protocol. You w ill not discl ose any of the information to others without 
written authorization from Gilead Sciences, Inc., except to the extent necessary to obtain informed consent from 
those persons to whom the drug may be administered.
PPD
PPD
PPD
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page2 10 July2014TABLE OF CONTENTS
TABLE OF CONTENTS ................................................................................................
....................................... 2
LIST OF IN- TEXT TABLES .................................................................................................................................5
LIST OF IN- TEXT FIGURES ............................................................................................................................... 5
PROTOCOL SYNOPSIS ....................................................................................................................................... 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS ............................................................ 16
1.INTRODUCTION ....................................................................................................................................... 19
1.1.Background ..................................................................................................................................... 19
1.2.Ledipasvir/Sofosbuvir Fixed -Dose Combination ............................................................................ 20
1.3.Rationale for the Current Study ...................................................................................................... 21
1.4.Rationale for Dose Selection of LDV/SOF FDC ............................................................................ 22
1.5.Overall Risk/Benefit Assessment .................................................................................................... 22
2.OBJECTIVES .............................................................................................................................................. 24
3.STUDY DESIGN ........................................................................................................................................ 25
3.1.Treatment Plan and Regimen .......................................................................................................... 25
3.1.1. PK Lead-in.................................................................................................................... 25
3.1.2. Treatment Phase ............................................................................................................ 25
3.2.Visit Schedule ................................................................................................................................. 27
3.2.1. PK Lead-in.................................................................................................................... 27
3.2.2. Treatment Phase ............................................................................................................ 28
3.3.Virologic Response- Based Stopping Criteria.................................................................................. 28
3.4.Treatment Discontinuations Criteria ............................................................................................... 28
3.5.Discontinuations ............................................................................................................................. 29
3.6.Pharmacogenomic Substudy ........................................................................................................... 29
3.7.Long-Term Follow-Up.................................................................................................................... 29
3.8.Breakthrough Futility Assessment .................................................................................................. 29
4.SUBJECT POPULATION ........................................................................................................................... 30
4.1.Number of Subjects and Subject Selection ...............................................................
...................... 30
4.2.Inclusion Criteria ............................................................................................................................ 30
4.3.Exclusion Criteria ........................................................................................................................... 31
5.INVESTIGATIONAL MEDI CINAL PRODUCTS.................................................................................... 33
5.1.Randomization and Blinding ........................................................................................................... 33
5.2.Ledipasvir/Sofosbuvir Fixed -Dose Combination ............................................................................ 33
5.2.1. Description and Handling .............................................................................................. 33
5.2.2. Storage and Handling .................................................................................................... 34
5.2.3. Dosage and Administration of LDV/SOF FDC ............................................................ 35
5.3.Study Drug Compliance .................................................................................................................. 36
5.4.Prior and Concomitant Medications ................................................................................................ 36
6.STUDY PROCEDURES ............................................................................................................................. 38
6.1.Subject Enrollment .......................................................................................................................... 38
6.2.Screening Assessments ................................................................................................................... 38
6.2.1. Screening Visit (Day –28 to Day 0) .............................................................................. 38
6.3.PK Lead-in: Treatment Assessments .............................................................................................. 40
6.3.1. Day 1 Visit.................................................................................................................... 40
6.3.2. Day 3............................................................................................................................. 41
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page3 10 July20146.3.3. Day 10 –Intensive PK .................................................................................................. 41
6.4.Treatment Phase: Treatment Assessments ...................................................................................... 43
6.4.1. Day 1 Visit................................
.................................................................................... 43
6.4.2. Weeks 1 and 2 ( 3 days).............................................................................................. 44
6.4.3. Weeks 4 and 8 ( 3 days)................................
.............................................................. 45
6.4.4. Week 12 ( 3 days)....................................................................................................... 46
6.4.5. Unscheduled Visit/Early Termination Visit .................................................................. 46
6.5.Post-Treatment Assessments ........................................................................................................... 48
6.5.1. 4-Week Post -Treatment Visit (5 days)....................................................................... 48
6.5.2. 12-Week Post -Treatment Visit ( 5 days)..................................................................... 48
6.5.3. 24-Week Post -Treatment Visit ( 5 days)..................................................................... 49
6.6.Procedures and Specifications ......................................................................................................... 49
6.6.1. Clinical Laboratory Analytes ...............................................................
......................... 49
6.6.2. Medical History ............................................................................................................. 50
6.6.3. Complete Physical Examination ................................................................................... 50
6.6.4. Tanner Pubertal Stage Assessment ................................................................................ 50
6.6.5. Height & Weight Measurement .................................................................................... 51
6.6.6. Bone Age Assessment ................................................................................................... 51
6.6.7. Swallowability Assessment ........................................................................................... 51
6.6.8. Vital Signs ..................................................................................................................... 51
6.6.9. Estimated Glomerular Filtration Rate (GFR) ................................................................ 51
6.6.10. Viral Sequencing (Archive) .......................................................................................... 51
6.6.11. Pregnancy Testing ......................................................................................................... 52
6.6.12. Quality of Life Survey (PedsQL™)................................................................................ 52
7.TOXICITY MANAGEMENT ..................................................................................................................... 53
7.1.Subject Stopping Rules for LDV/SOF FDC ................................................................................... 53
8.ADVERSE EVENTS MANAGEMENT ..................................................................................................... 54
8.1.Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events .......................... 54
8.1.1. Adverse Events .............................................................................................................. 54
8.1.2. Serious Adverse Events................................................................................................. 54
8.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments 
as Adverse Events or Serious Adverse Events .............................................................. 55
8.2.Assessment of Adverse Events and Serious Adverse Events .......................................................... 55
8.2.1. Assessment of Causality for Study Drugs and Procedures ............................................ 55
8.2.2. Assessment of Severity ................................................................................................. 56
8.3.Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead or CRO .................................................................................................. 56
8.4.Gilead Reporting Requirements ...................................................................................................... 58
8.5.Special Situations Reports .............................................................................................................. 58
8.5.1. Definitions of Special Situations ...............................................................
.................... 58
8.5.2. Instructions for Reporting Special Situations ................................................................ 59
9.STATISTICAL CONSIDER ATIONS......................................................................................................... 61
9.1.Analysis Objectives and Endpoints ................................................................................................. 61
9.1.1. Analysis Objectives ....................................................................................................... 61
9.1.2. Primary Endpoints ......................................................................................................... 62
9.1.3. Secondary Endpoints ..................................................................................................... 62
9.2.Analysis Conventions ..................................................................................................................... 62
9.2.1. Analysis Sets ................................................................................................................. 62
9.2.2. Data Handling Conventions .......................................................................................... 63
9.2.3. Interim Analysis ............................................................................................................ 64
9.3.Demographic Data and Baseline Characteristics ............................................................................ 64
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page4 10 July20149.4.Pharmacokinetic Analysis ............................................................................................................... 64
9.5.Safety Analysis ................................................................
............................................................... 66
9.5.1. Extent of Exposure ........................................................................................................ 66
9.5.2. Adverse Events ...............................................................
............................................... 66
9.5.3. Laboratory Evaluations ................................................................................................. 67
9.5.4. Other Safety Evaluations ............................................................................................... 67
9.6.Efficacy Analysis ...............................................................
............................................................. 68
9.6.1. Primary Efficacy Analysis ............................................................................................ 68
9.6.2. Secondary Efficacy Analysis ........................................................................................ 68
9.6.3. Subgroup Analysis ........................................................................................................ 68
9.7.Quality of Life Analysis .................................................................................................................. 69
9.8.Data Monitoring Committee ........................................................................................................... 69
9.9.Sample Size..................................................................................................................................... 69
10.RESPONSIBILITIES .................................................................................................................................. 70
10.1.Investigator Responsibilities ................................
........................................................................... 70
10.1.1. Good Clinical Practice .................................................................................................. 70
10.1.2. Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) Approval ............................................................................................................. 70
10.1.3. Informed Consent/Assent .............................................................................................. 71
10.1.4. Confidentiality .............................................................................................................. 71
10.1.5. Study Files and Retention of Records ........................................................................... 71
10.1.6. Case Report Forms ........................................................................................................ 73
10.1.7. Drug Accountability ...................................................................................................... 73
10.1.8. Inspections .................................................................................................................... 73
10.1.9. Protocol Compliance ..................................................................................................... 73
10.2.Sponsor Responsibilities ................................................................................................................. 74
10.2.1. Protocol Modifications .................................................................................................. 74
10.2.2. Study Report and Publications ...................................................................................... 74
10.3.Joint Investigator/Sponsor Responsibilities .................................................................................... 74
10.3.1. Access to Information for Monitoring ........................................................................... 74
10.3.2. Access to Information for Auditing or Inspections ....................................................... 75
10.3.3. Study Discontinuation ................................................................................................... 75
11.REFERENCES ............................................................................................................................................ 76
12.APPENDICES ............................................................................................................................................. 77
Appendix 1.Investigator Signature Page ............................................................................................. 78
Appendix 2.Study Procedures Table ................................................................................................... 79
Appendix 3.GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities.................................................................................................................. 84
Appendix 4.Tanner Stages ................................................................................................................ 107
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ......................................................................................... 108
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page5 10 July2014LIST OF IN -TEXT TABLES
Table5-1. Disallowed and Concomitant Medications to be Used w ith Caution .............................. 37
Table9-1. SOF, GS-331007, and LDV PK Parameters after Once -Daily Administration of 
SOF/LDV in HCV -Infected Adults Subjects (Population PK Analysis from 
Phase2 and 3 Studies) ................................
..................................................................... 66
LIST OF IN -TEXT FIGURES
Figure3-1.Study Schema .................................................................................................................. 27
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page6 10 July2014PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404, USA
Study Title: A Phase 2, Open -Label, Multicenter, Mu lti-cohortStudy to 
Investigate the Safety  and Efficacy of Ledipasvir/Sofosbuvir Fixed 
Dose Combination in Adolescents and Children with Chronic 
HCV-Infection
IND Number:
EudraCT Number:115268
TBD
Study Centers: Approximately  50 sites in the United States, Europe, Russia, 
Australia, and New Zealand
Number of Subjects: Approximately  200subjects
Target Population: Adolescents and children (aged 3 to < 18) chronic hepatitis C virus 
(HCV) infection
Treatment Duration: PK Lead-in – 10days
Treatment Phase – 12 weeks
Objectives: The primary  objective of the PK Lead- in Phase of this study  is:
To evaluate the steady state pharmacokinetics (PK) and 
confirm the dose of LDV/SOF FDC in chronic HCV-infected 
pediatric subjects
The secondary  objective of the P K Lead-in Phase of this study  is:
To evaluate the safet y,tolerability , and antiviral activity of 
10days of dosing of LDV/SOF FDC in chronic HCVinfected 
pediatric subjects
The primary  objective of the Treatment Phase of this study  is:
To evaluate the saf ety and tolerability  of LDV/SOF FDC for 
12weeks in chronic HCV -infected pediatric subjects. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page7 10 July2014The secondary  objectives of the Treatment Phase of this study  are:
To determine the antiviral efficacy  of 12 weeks of LDV/SOF 
FDC treatment in chronic HCV infectedsubjects(including the 
impact of HCV genot ype, IL28 genot ype, and prior treatment 
experience) ,as assessed by  the proportion of subjects with 
sustained virological response (SVR) 12 weeks after 
completion of treatment (SVR12)
To determine the an tiviral efficacy  of 12 weeks of LDV/SOF 
FDC treatment in chronic 
HCV-infected subjects, as assessed 
by the proportion of subjects with SVR 4 and 24 weeks after 
completion of treatment (SVR4 and SVR24)
To evaluate the kinetics of circulating HCV RNA during 
treatment and after completion of treatment
To evaluate the emergence of viral resistance to LDV and SOF 
during treatment and after completion of treatment
To evaluate the effect of growth and development on pediatric 
subjects during and after treatment
The exploratory  objective of this study  is:
  
 
Study Design: Open-label, multi -cohort, two -part study evaluating the PK, safet y, 
and antiviral activity of LDV/SOF FDC in chronic HCV -infected 
pediatric subjects.
The study  will be divided into 2 parts and will commence with 
GT-1 HCV-infected pediatric subjects as follows (subjects with 
GT-2, -4, -5, and -6 will be included once adult data is available, if 
appropriate) :
PK Lead -in Phase : PK Lead-
in will evaluate and /or confirm age 
appropriate LDV/SOF FDC doses by  analyzing PK, safet y, and 
antiviral activity  of LDV/SOF FDC through 10 days of dosing for 
each of the three cohorts. Children aged 3 to < 6, children aged 
6to<12 years,and adolescents aged 12 to < 18 with years 
evidence of chronic HCV and HCV RNA ≥ 1000 IU/mL at study 
entry will be evaluated.  Subjects must be treatment naïve to 
participate in the PK Lead- in Phase.  
Three cohorts of at least10 subjects each will be sequentially  
enrolled: 
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page8 10 July2014Cohort 1: 12 to < 18 y ears,old weighing ≥ 45kg
Cohort 2: 6 to < 12 y ears old 
Cohort 3: 3 to < 6 y ears old 
The study  will start with Cohort 1.  Subjects will receive 
LDV/SOF FDC ( 90mg/ 400 mg fixed dose combination tablet or 
4x 22.5mg/ 100mgbased on LDV/SOF FDC swallowability  
assessment ) for 10days with intensive PK conducted on Day  10.
PK Lead-in subjects in each cohort (Cohorts 1, 2 and 3) will 
immediately  enroll in the Treatment Phase as they complete 
Day10of the PK Lead -in Phase. They  will continue dos ing with 
LDV/SOF FDC with no interruption of study  drug administration. 
Subjects rolling over from the PK L ead-in will not be required to 
perform Treatment Phase Screening, Day  1, or Week 1 visits in the 
Treatment Phase.  
Following completion of study  treatment in the PK L ead-in of each 
Cohort, intensive PK and safet y results of study treatment will be 
reviewed to confirm the appropriateness of the evaluated 
LDV/SOF FDC dose for the Treatment Phase of that Cohort as 
well as to determine the age-
appropriate dose to be evaluated in the 
PK Lead-in of the next Cohort . 
Treatment Phase : Treatment Phase will be initiated sequentiall y 
by cohort after confirmation of age- appropriate LDV/SOF FDC 
dosage levels. Subjects who participate in PK Lead -in Phase will 
immediately  rollover into Treatment Phase, with no interruption of 
study drug administration ,until the appropriateness of the dose is 
confirmed b yPK and safety  data from the PK Lead-In Phase.  
These subjects will start at the Week 2 visit of the Treatmen t 
Phase. Additional subjects will be enrolled in the Treatment Phase 
of each Cohort upon confirmation of the appropriateness of the 
dose.
Children aged 3 to < 12 years and adolescents aged 12 to 
<18years with chronic HCV -infection and a HCV RNA 
≥ 1000IU/mL at study  entry (those who were dosed in the PK 
Lead-in Phase will have met this criteria prior to enrollment) will 
be evaluated. The stud y will commence with GT -1 HCV infected 
pediatric subjects and will subsequently  enroll subjects with GT-2, 
-
4, -5, and -6 once adult data is available, if appropriate . 
All subjects enrolled in the study  will receive the following 
regimen:
LDV/SOF FDC for 12 weeks
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page9 10 July2014The study  will enroll both treatment -naïve and treatment
experienced pediatric subjects, with up to 40 sub
jects allowed to be 
treatment experienced. Approximately  200 total subjects, including 
subjects that participated in the PK L ead-in Phase, will be enrolled 
in Treatment Phase as follows:
Group 1: Approximately  100 adolescent subjects (12 to 
<18years of age)
Group 2: Approximately  100 pediatric subjects (3 to < 12years 
of age)
The following definitions will be used for treatment experienced 
subjects: 
Interferon intolerant: Subject who discontinued therap y 
(≤ 12 weeks total) due to ≥ 1 adverse event 
Interferon non- responder: Subject who did not achieve 
undetectable HCV RNA levels while on treatment 
Relapse/breakthrough: Subject who achieved undetectable 
HCV RNA during treatment or within 4 weeks of the end of 
treatment but did not achieve a sustained vir ologic response 
(SVR)
The study  schedule contains the following visits: Screening, Day 1, 
Weeks 1, 2, 4, 8, and 12 during the treatment phase followed b y 
post-treatment visits 4, 12 and 24 weeks after discontinuation of 
therapy.
All subjects who do not a ttain SVR or have viral relapse will be 
encouraged to discuss treatment with standard -of-care (SOC) 
therapy with their healthcare provider.
Substudy and 
Long-Term 
Follow-Up Study :Pharmacogenomics (PG) Substudy
 
Long-Term Follow -up
Subjects who attain SVR24 or those who do not attain SVR24 and 
do not initiate expe rimental or approved anti -HCV therapy  will be 
followed every  6 months for assessments of growth, quality  of life, 
and long-term viral suppression (if applicable) in a separate 
protocol (GS -US-334-1113). Thi s follow-up will continue for 
5years.
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page10 10 July2014Diagnosis and Main 
Eligibility  Criteria: Chronic HCV -infected, treatment -naïve and treatment experienced
(up to 4
0 subjects)
,male and female subjects aged 3 to < 18as 
determined at Day  1. The study  will commence with GT -1 
HCV-infected 
pediatric subjects and will subsequently  enroll 
subjects with GT -2, -4, -5 and -6 once adult data is available, if 
appropriate . 
Inclusion Criteria:
Chronic HCVinfection documented b y either:
A)a positive anti
-HCV antibody  test or positive HCV RNA or 
positive HCV genot yping test at least 6 months prior to the 
Day 1visit, or
B)a liver biopsy performed prior to the Day 1visit with 
evidence of chronic HCV -infection
HCV RNA ≥ 1000 IU/mL at Screening
For the PK Lead -in Phase:  subj ects in Cohort 1 (age 12 to 
<18years of age) must weigh ≥ 45 kg
Sexually active subjects must a gree to use 2 forms of highl y 
effective contraception, as referenced in Appendix 5,for the 
duration of the study  and for 30 d ays (for female subjects) or 
90 days (for male subjects) after the last dose of study  
medication. Females of childbearing potential (as defined in 
Appendix 5)must have a negative pregnancy test at Screening 
and Day 1.
Exclusion Criteria:
Hematologic or biochemical parameters at screening outside 
the protocol -specified requirements
HIV, acute hepatitis A virus (HAV) or chronic HBV infection
History of or current decompensated liver disease
Hepatocellular carcinoma or other malignancy  (with exception 
of certain resolved skin cancers)
Chronic liver disease of a non- HCV etiology  
(eg,hemochromatosis, Wilson’s disease, alpha -1 antitrypsin 
deficiency )
Systemic corticosteroid use for 2 weeks(pulmonary /nasal 
administration is permitted)
Active or recent history  (≤ 1 year) of drug or alcohol abuse
History or current evidence of an y condition, therapy , 
laboratory  abnormality  or other circumstance that might 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page11 10 July2014confound the results of the study , or interfere with the subject’s 
participation for the full duration of  the study , such that it is 
not in the best interest of the subject to participate.
See Sections 4.2 and 4.3of the protocol for full eligibility  criteria.
Study Procedures/
Frequency :PK Lead -in Phase: 
Screening assessments will be completed within 28 day s of the 
Day 1 visit. 
Screening a ssessments will include: complete physical 
examination, vital sign s (including body  height and weight) , 
adverse events ( AEs),concomitant medications, LDV/SOF FDC 
Swallowability  Assessment (may  be performed at screening up to 
Day 1), hematology , safety laboratory  tests, coagulation tests, 
HCV RNA, serum β-human chorionic gonadotropin (hCG-
females of childbearing potential only ), urinalysis, and urine drug 
screen,IL28B genot yping,serology (HIV, HAV, HCV, and HBV),
HbA1c, thyroid stimulating hormone (TSH), alpha fetoprotein,
alpha-1 anti-trypsin.
Study Visits will occur at Screening, Day  1, Day 3, and Day 10.
On-Treatment assessments include phy sical examination ,Tanner 
Pubertal Stage Assessment (Day 1 only), vital signs (including 
body height and weight), bone age assessment (Day  1 only),
adverse events (AEs), concomitant medications, pregnancy  
prevention counseling (Day 1 only ; all subjects ≥ 12 years of age
andsubjects < 12 years of age at the discretion of the Investigator 
based on subject’s pubertal status),quality of life survey  (Day 1 
only), safety laboratory  tests, HCV RNA, viral sequencing 
sampling, and urinalysis.  Coagulation testing and urine pregnancy  
tests (females of child bearing potential only ) will be performed at 
Day 1 and Day  10 only. LDV/SOF FDC swallowability  assessment 
with placebo will be performed at Screening or up to Day1 to 
assess a subject’s ability to swallow the 
90 mg/400mg or 22.5
mg/100mgFDC tablet (only subjects administered LDV/SOF 
FDCin tablet form) . 
Subjects ( atleast10 subjects per cohort ) enrolled in the PK 
Lead-in Phase will participate in an intensive PK evaluation on 
Day 10. Following completion of the Day  10intensive PK visit, 
subjects will then return for scheduled stud y visits outlined in the 
Treatment Phase and will continue dosing with LDV/SOF FDC 
with no interruption of study  drug administration. Subjects will be 
administered a dosing diary  with instructions.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page12 10 July2014Treatment Phase: 
Screening assessments will be completed within 28 day s of the 
Day 1 visit. For subjects continuing from PK Lead- in, screening 
for Treatment Phase will not be required.
Screening assessments will include complete physical examination, 
vital signs (including body  height and weight) , AEs, concomitant 
medications, coagulation, safety laboratory  tests, HCV RNA, 
serum β-human chorionic gonadotropin (hCG
-females of 
childbearing potential only ), urinalysis, urine drug screen, serology 
(HIV, HAV, HCV, HBV), IL28B genot yping,HbA1c, TSH, alpha 
fetoprotein, alpha-1 anti-trypsin.LDV/SOF FDC swallowability  
assessment with placebo will be performed at Screening or up to 
Day1 to assess a subject’s ability  to swallow the 90 mg/ 400 mg or 
22.5 mg/ 100 mg FDC tablet (only subjects administered 
LDV/SOF FDC in tablet form) .
Study visits will occur at Screening, Day  1, and at the end of 
Weeks 1, 2, 4, 8, and 12. All Treatment Phase subjects will then 
return for follow -up visits at 4, 12 and 24 weeks after 
discontinuation of therapy . 
On-treatment assessments will include physical examination, vital 
signs (including body height and weight), AEs, concomitant 
medications, pregnancy  prevention counseling ( all subjects 
≥ 12years of age andsubjects < 12 y ears of age at the discretion of 
the Investigator based on subject’s pubertal 
status),safety 
laboratory  tests, coagulation tests, HCV RNA, viral sequencing, 
urine pregnancy  tests (females of childbearing potential only ),PK 
samples, and urinal ysis. Tanner Pubertal Stage assessment will be 
performed at Day 1, end of treatment, post -treatment Week 12, and 
post-treatment Week 24 visits; parental heights will be recorded at 
Day1. The Bone Age Assessme nt will be performed at the Day 1 
and post-treatment Week 24 visits. If available, results from liver 
biopsies will be collected at screening. LDV/SOF FDC 
swallowability  assessment will be performed at screening or up to 
Day1 to assess a subject’s ability  to swallow a placebo to match 
the 90mg/400mg 
or 22.5 mg/100mgLDV/SOF FDC tablet
(only subjects administered LDV/SOF FDC in tablet form) . For 
subjects continuing from the PK Lead -in, the screening, Day 1,and 
Week1 visits of the Treatment Phase will not be required. Samples 
for viral RNA sequencing/phenot yping will be collected at Day 1 
and every  visit thereafter.
Post-treatment assessments will include vital signs (including bod y 
weight and height) , symptom-directed ph ysical examination, AEs 
(only SAEs will be captured at post-treatment Wee k 12 and 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page13 10 July2014post-treatment Week 24) , concomitant medications (only 
post-treatment Week 4), safety laboratory  tests, HCV RNA, and 
urine pregnancy  tests (only females of childbearing potential at 
post-
treatment Week 4 and post- treatment Week 12).  
 
 
Test Product, Dose, 
and Mode of 
Administration:PK Lead -in: 
(Cohort 1) LDV/SOF FDC is manufactured as a tablet, consisting 
of 400mg SOF and 90 mg LDV, for oral administration.  
LDV/SOF FDC tablets will be administered once daily . Subjects 
unable to swallow the LDV/SOF FDC 90 mg/400 mg adult tablet s
(as determined by
 LDV/SOF FDC Placebo swallowability  
assessment at Screening or at an y time during the study ) will be 
re-assigned to 4 x 22.5 mg/ 100mg LDV/SOF FDC tablets daily .
Intensive PK and safet y results from the PK Lead-i n of each 
Cohort will be reviewed to confirm the appropriateness of the 
evaluated LD V/SOF FDC dose for the Treatment Phase of that 
Cohort as well as to determine the age -appropriate dose to be 
evaluated in the PK Lead -in of the next Cohort.
Treatment Phase: 
Subjects who participated in PK L ead-in of each Cohort will 
continue in the Treat ment Phase with no interruption of study  drug 
administration until the appropriateness of the dose is confirmed by  
PK and safet y data from the PK -Lead-in. Additional subjects will 
be enrolled in the Treatment Phase of each Cohort upon 
confirmation of the a ppropriateness of the dose.
Reference Therapy: None
Evaluation Criteria:
Safety: AEs, laboratory  tests, phy sical examinations, and vital sign 
measurements will be collected throughout the study . 
Efficacy: Efficacy will be evaluated using scheduled assessments of HCV 
RNA performed using COBAS®AmpliPrep/COBAS®TaqMan®
HCV Test .
PK: For subjects in the PK Lead -in, a steady-state PK of LDV, SOF,
and its major metabolites ( GS-566500 and GS -331007)will be 
assessed at Day 10. For Cohorts 1 and 2, plasma samples will be 
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page14 10 July2014collected for PK anal yses followi ng dosing of study  drugs on 
Day10at the following time points: 0 (predose), 0.5, 1, 2, 3, 4, 5, 
8, and 12 hours postdose (with predose also serving as t= 24). For 
Cohort 3, plasma samples for PK anal yses will be collected at the 
following time points: 0 (predose), 0.5, 2, 4, 8, and 12 hours 
postdose (with predose also serving as t = 24).
Plasma PK 
parameters such as C max, Tmax, Clast, Tlast, Ctau, AUC tau, 
and t1/2 will be estimated. 
For all subjects in the Treatment Phase, a single PK blood sample 
will be collected at all visits while on treatment. The PK of SOF, 
GS-566500 and GS -331007,and LDV wi ll be assessed.
The effect of age and LDV /SOF FDC dose on PK (SOF, 
GS-331007, and LDV) will be explored.
Statistical Methods: For the PK Lead -in, plasma PK parameters C max, Tmax, Clast, Tlast, 
Ctau, AUCtau, and t1/2will be estimated. The PK parameters wi
ll be 
summarized by  cohort. The effect of age and LDV/SOFFDCdose 
on PK (SOF, GS -331007
,and LDV) will be explored.
For the Treatment Phase, the primary  safety endpoint is any AE 
leading to permanent discontinuation of study  drug and will be 
summarized by age group, by  GT,and by overall. Primary efficacy 
endpoint is SVR12 in all enrolled and treated subjects and will be 
summarized by  age group, by  GT, by overall,and by age group 
and GT. Point estimate and its 95% confidence interval will be 
provided. 
Subgroup anal ysis on SVR12 will be performed by  prior treatment 
experience (treatment -naïve vs. treatment 
experienced) and b y GT. 
Other clinicall y relevant subgroup anal yses may be conducted as 
appropriate (i.e., assuming that adequate numbers of patients in 
these subsets are available for anal ysis). 
All continuous endpoints will be summarized using an 8 -number 
summary (n, mean, standard deviation, median, Q1, Q3, minimum, 
and maximum). All categorical endpoints will be summarized by  
number and percentage of subjects who meet the endpoint 
definition.
Safety endpoints will be anal yzed by the number and percent of 
subjects with events or abnormalities for categorical values or 
8-number summary  (n, mean, standard deviation, median, Q1, Q3, 
minimum, maximum) for continuous data by  age group, by  GT, by 
overall,and by age group and GT.
With approximately  100 subject s enrolled into each age group of 
Treatment Phase, a two -sided 95.0% confidence interval of the 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page15 10 July2014SVR12 rate will extend at most 5.9% in both directions from the 
observed SVR12 rate, assuming the expected SVR12 rate is 90%.
This study  will be conducted in accordance with the guidelines of Good Clinical Practices 
(GCPs) including archiving of essential documents.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page16 10 July2014GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
AE adverse event
ALT alanine aminotransferase (also SGPT)
ANC absolute neutrophil count
APTT activated partial thromboplastin time
AST aspartate aminotransferase  (also SGOT)
AUC area under the curve
AUCtau area under the plasma concentration versus time curve over the dosing interval 
(tau)
BLQ below the lower limit of quantification
BMI body mass index
CK creatine kinase
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
Ctau observed drug concentration at the end of the dosing interval (tau)
CRF case report form(s)
CRO Contract (or clinical) research organization 
DAA Direct acting antiviral
dL Deciliter
DNA deoxyribonucleic acid
DMC Data Monitoring Committee
DSPH Drug Safety and Public Health
ECG Electrocardiogram
eCRF Electronic case report form(s)
ESA Erythropoiesis stimulating agent
ESPGHAN European Society for Paediatric Gastroenterology
EU European Union
FAS full analysis set
FDA (United States) Food and Drug Administration
FDC Fixed-Dose Combination
FEV1 forced expiratory volume in one second
GCP Good Clinical Practice (Guidelines)
GCSF Granulocyte colony stimulating factor
GFR glomerular filtration rate
GGT gamma glutamyl transferase
GSI Gilead Sciences, Inc.
GT Genotype (viral)
GSI Gilead Sciences, Inc.
GT Genotype (viral)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page17 10 July2014GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS (CONTINUED)
HAV Hepatitis A Virus
Hb Hemoglobin
HbA1c Hemoglobin A 1c
HBV Hepatitis B virus
HCV Hepatitis C virus
HDPE high-density polyethylene
HIV Human Immunodeficiency Virus
HLGT High-Level Group Term
HLT High-Level Term
ICH International Conference on Harmonisation
IEC independent ethics committee
IL28B IL28B gene
IND Investigational New Drug (Application)
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
kg Kilogram
L Liter
LDV Ledipasvir
LLN lower limit of the normal range
LLOQ Lower limit of quantification
LLT Lower-Level Term 
MedDRA Medical Dictionary for Regulatory Activities
Mg Milligram
MH Mantel-Haenszel
mL Milliliter
Min Minute
mmHg millimeters mercury
NS (3/4A/5A/5B) Non-structural Protein
PBMC peripheral blood mononuclear cell(s)
PEG peginterferon alfa
-2a
P-gp P-glycoprotein
PI Protease inhibitor
PK Pharmacokinetic
QD once daily (use only in tables)
RBC Red blood cell count
RBV ribavirin
RNA ribonucleic acid
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page18 10 July2014GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS (CONTINUED)
SADR Serious adverse drug reaction
SAE serious adverse event
SD Standard deviation
SOC Standard-of-Care
SOF Sofosbuvir
SOP Standard operating procedure
SUSAR Suspected Unexpected Serious Adverse Reaction
SVR Sustained Virologic Response
tmax The time (observed time point) of Cmax
TSH Thyroid stimulating hormone
t½ An estimate of the ter minal elimination half-life of the drug in 
serum/plasma/PBMC, calculated by dividing the natural log of 2 by the terminal 
elimination rate constant (λz)
ULN upper limit of the normal range
US United States
WBC white blood cell count
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page19 10 July20141. INTRODUCTION
1.1. Background
Hepatitis C virus (HCV) is responsible for a large proportion of chronic liver disease 
worldwide and accounts for 70% of cases of chronic hepatitis in industrialized countries. The 
global prevalence of chronic hepatitis C is estimated to average 3% {19705}. 
Thenatural history  of chronic HCV -infection in children differ s from that in adults since 
HCV-infection in children is relatively  benign. Most children chronically  infected with HCV 
are asymptomatic or have mild nonspecific s ymptoms. Clinical sy mptoms are present in 
approximately  20% of children in the first 4 y ears of life, with hepatomegaly  beingthe most 
frequent sign (10%). Many, but not all, perinatally  infected children will have intermittently  
or persistently  abnormal alanine aminotransferase (ALT
)or aspartate aminotransferase 
(AST) levels, particularly  in the first 2 y ears of life . In children with vertical HCV -infection 
who have undergone liver biopsy , the histological spectrum is usually  mild, although severe 
liver disease is encountered {19801}. Despite the overal l more favorable prognosis compared 
to adults, approximately  4% to 6% of children with chronic HCV-infection have evidence of 
advanced fibrosis or cirrhosis and some children eventuall y require liver transplantation for 
end-stageliver disease as a consequence of HCV -infection {19799}.
The goal of HCV treatment in both pediatric and adult populations is eradication of the virus, 
thereby preventing hepatic inflammation, hepatic fibrosis, cirrhosis, and liver failure 
resulting in either deat h or need for liver transplantation. This goal, however, is limited by  
the nature of the disease and the fact that not all patients are suitable candidates for currentl y 
approved treatments. In addition, pediatric treatment is controversial as the current treatment 
options are limited and severe side effects and tolerability  can significantl y limit or preclude 
their use. Despite well -established guidelines for the treatment of HCV in adults, there is no 
universal consensus on when or if to treat chronic HCV-infection in children. I n 2010, the 
European Societ y for Paediatric Gastroenterology , Hepatology , and Nutrition (ESPGHAN) 
issued guidance for clinical trial development for chronic HCV-infection in children {20286}.
In the guideline, the ESPGHAN suggested that the primary  goal of treatment in children is to 
eradicate the infection to prevent late complications. Hence, the goal is not the t reatment of 
an ongoing liver disease, but rather the prevention of a future one.
PEGand weight -based RBV are currentl yconsidered the SOCfor the treatment of 
HCV-
infection in children. Current recommendations are that patients with GT -2 or GT-3 be 
treatedwith PEG+RBVfor 24 weeks and those with GT -1 or GT
-4 should receive 48 weeks 
of therapy. Successful treatment of GT -1, however, has proved very  difficult to achieve in 
spite of additional therapy or increased duration of treatment. A number of pediatric studies 
have reported that despite 48 weeks of treatment, sustained virologic response (SVR24) was 
observed in onl y 36% to 53% of subjects with GT -1, while response rates were > 80% in 
subjects with GT -2 or GT-
3{20285}.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page20 10 July2014Most children treated with PEG+RBV experience at least 1 adverse event due to treatment 
{20285}. Although most of these events are mild to moderate in severity , many of them result 
in dose reductions of 1 or both of the drugs. The most common adverse events have consisted 
of influenza-like illness (91%), headache (62%), and injection site reactions (45%), often 
leading to poor compliance and/or discontinuation from treatment.
Additionally , t
he concern for growth and development in this age group and the role that both 
PEGand RBV po tentially play in reducing growth rates has initiated significant debate 
among pediatric hepatologists as to whether these treatments should even be considered in 
the pediatric population {20282}.Many pediatricians currentl y advocate delay of treatm ent 
past adolescence or even into adulthood when options with DAAs are possible {20282}. 
Unfortunatel y, in the 25% of pediatric patients who do meet the criteria for treatment 
(elevated transaminases and viral loads), the option of PEG+RBV therap y remains 
inadequate in regard to both efficacy  in GT-1 and safet y due to the man y risks associated 
with this treatment.
1.2. Ledipasvir/Sofosbuvir Fixed-Dose Combination
Ledipasvir/S ofosbuvir fixed -dose combination ( LDV/SOF FDC) combines two HCV specific 
direct acting antiviral (DAA)agents into a single tablet for the treatment of chronic HCV-
infection. SOF is a nucleotide analog that is a potent and selective inhibitor of NS5B -directed 
HCV replication with demonstrated activity  against GT 1-6 HCV-infection. Ledipasvir 
(LDV) is a novel HCV NS5A inhibitor that has demonstrated potent anti -HCV activity , with 
the highest activity  against GT1 HCV-infection.  
The LDV/SOF phase 3 program consist edof 3 clinical studies: GS- US-337-0102 { 28583}, 
GS-US-337-
0109 {28585}, and GS-US-337- 0108 {28587}. Studies GS -US-337-0102 and 
GS-US-
337-0109 evaluated treatment with LDV/SOF FDC RBV for 12 or 24weeks in 
treatment -naïveand treatment experienced subjects, respectivel y, infected with GT -1 HCV. 
Both studies enrolled up to 20% of HCV
-infected subjects who had documented 
compensated cirrhosis. GS-US-337-0108 evalua ted LDV/SOF FDC ± RBV treatment for 
8weeks and LDV/SOF FDC treatment for 12 weeks in non -cirrhotic treatment
-n
aïvesubjects 
with GT-1 HCV -infection. Across the se3 clinical studies, LDV/SOF FDC demonstrated a 
high degree of efficacy  (>93%) for treatment-n
aïveand treatment experienced subjects with 
GT-1 HCV-infection in subjects with and without cirrhosis andachievedtheir primary  
efficacy endpoints {28583};{28585
};{28587}. Additionally , treatment with L DV/SOF FDC ± 
RBV was safe and well tolerated in the Phase 3 studies{28583};{28585};{28587}.  The 
inclusion of RBV to the treatment regimen was associated with an increase in the total 
incidence of adverse events and in graded laboratory  abnormalities of anemia and increased 
bilirubin. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page21 10 July2014Please refer to the Investigator’s Brochure (IB) for additional information on the L DV/SOF 
FDC including:
In Vitro Anti -Hepatitis C Virus Activity
Nonclinical Pharmacokinetics and In Vitro Metabolism
Nonclinical Pharmacology and Toxicology
Clinical Experience
1.3. Rationale for th e Current Study
This clinical study  is designed to evaluate the efficacy  and safet y of treatment with 
LDV/SOF FDC for adolescents and children with chronic HCV -infection. 
Currently
 PEGand weight -based RBV are considered the SOCfor the treatment of HCV -
infection in children. Therefore, there isa need for new treatments for HCV in the pediatric 
population that combine potent and sustained efficacy  with improved tolerability  and safet y. 
The primary  aim for newtreatment sof pediatric patients with HCV is to eliminate the need 
to use PEG. I n this way , pediatric patients would be able to avoid the necessity  of weekly 
injections which can be traumatic and burdensome and significantl y reduce the serious 
adverse events seen with PEG administration. The secondar y aim is to eliminate RBV and 
the adverse events seen with its administration. Consequently, LDV/SOF FDC has the 
potential to be a simple and highl y effective all -
oral treatment regimen for chronic HCV-
infection with treatment duration of 12 weeks without PEG or RBV for some GTs. 
In vitro viral replicon assay  have data demonstrated that L DV has potent, picomolar antiviral 
activity against GT-1a and GT-1bHCV-infection. In the LDV/SOF FDC phase 3 program, 
LDV/SOF FDC without RBV has been shown to have good efficacy  and safet y in adults 
infected with GT-1 HCV-infection.  In 
study GS-US-337-0122, a phase 2 open- label study of 
GT-3 treatment -naïveadult subjects with and without cirrhosis, LD V/SOF FDC for 12 weeks 
resulted in an SVR12 of 64% whereas LDV/SOF + RBV for 12 weeks resulted in an SVR of 
100% {29292}.  As a result, the current stud y which does not include RBV in the treatment 
regimen will initially  
only enroll pediatric subjects with GT -1 HCV-infection and will not 
enrollsubjects with GT -3.
Considering that SOF has pan- genotypic activity and LDV has in vitro, picomolar to 
nanomolar antiviral activity against certain subt ypes within GT 4-6 and sub -micromolar 
antiviral activity against certain subt ypes within GT-2, studies have been planned and/or
initiated with LDV/SOF FDC in adult subjects with GT-
2, -4, -5, and -
6.  If emerging 
LDV/SOFFDC data in these additional GTs support treatment in these genoty pesin adults,
pediatric subjects with GT -
2, -4, -5 and -6will be enrolled in the current study .  Of note, 
there is an ongoing study enrolling GT -2 and -3 pediatric patients, GS- US-334-1112, for 
treatment with SOF + RBV for 12 and 24 weeks, respectivel y.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page22 10 July20141.4. Rationale for Dose Selection of LDV/SOF FDC
Ledipasvir /Sofosbuvir 
(90 mg/400 mg ) fixed-dose combination tablet, administered once 
daily, has demonstrated favorable safet y and efficacy  profiles in over 1952 HCV-infected 
subjects across different patient populations in p
hase 2 and 3 clinical trials. These doses are 
the proposed marketed dose of a ledipasvir/sofosb uvir 
fixed-dose combination tablet for the 
treatment of HCV -infection.
Selection of doses of LDV/SOFFDC for adolescents and y ounger age groups will target 
systemic exposures similar to those observed in adults at the proposed marketed dose and
taking into account bod y weight/bod y surface area, the potential ontogenic changes in 
intestinal and hepaticall y expressed carbox ylesterase (CES1) and Cathepsin A (CatA) 
enzymes, the drug transporter p- glycoprotein (Pgp), and the results obtained in older age 
groups.  Available data suggests comparable hepatic expression of CES1 in adolescents and 
adults with modestly  decreased expression in children.  However, little is known about the 
developmental regulation of Pgp, CES, and CatA.  As such, the adult cl inical dose s (90mg /
400mg)will be evaluated in adolescents (12 to <18 y ears old).  Safet y and PK data in the 
adolescent group (Cohort 1) in the PK Lead- in, in addition to body  weight/body  surface area 
will inform dose selection for the younger age grou
ps.
Age-appropriate formulations of L DV/SOF FDC (a smaller, 22.5 mg /100 mg strength tablet 
and a non- tablet formulation currentl y under development) that offer an important option in 
the treatment of HCV-infection in the pediatric population are planned for evaluation in 
children below 12 years of age or children who are unable to swallow the adult dose tablet 
formulation.
1.5. Overall Risk/Benefit Assessment
Although the majorit y of pediatric patients infected with HCVexhibit minimal hepatic
sequelae despite active viral replication and inflammation, a subset of children and
adolescents will require treatment. Studies suggest that 3 major categories of disease can
occur within 10 
years after putative HCV exposure: (1) undetectable viremia and normal
ALT, (2) persistent y et uncomplicated mild liver disease, and (3) progression to end- stage
liver disease {20273}.It is the last twogroupsof children in whom therapy  maybeindicated 
to prevent end -stage disease, either during childhood/adolescence or in early adulthood.
Given that the current SOCfor the treatment o f children infected with HCV is PEG and RBV 
and these regimens are long in duration, relativel y toxic, and not welltolerated, there 
continues to be a need for new treatments for HCV that combine potent and sustained 
efficacy with improved tolerability  and safet y. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page23 10 July2014The combination of LDV plus SOF is anticipated to offer greater antiviral efficacy  which 
could resul t in a shorter treatment duration and/or lead to a regimen without RBV or 
interferon. These in turn could result in reduction in adverse events.  LDV/SOF FDC could 
also potentially  be of benefit in patients who have failed prior treatment with SOF+/ -RBV+/-
PEG.
If high rates of SVR can be obtained with short, well
-tolerated regimens, the anticipated 
improvements in safet y and tolerability would offer a favorable risk -benefit determination for 
individuals with chronic HCV-infection.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page24 10 July20142. OBJECTIVES
The primary  objective of the PK Lead -inPhase of this study  is:
To evaluate the stead y state pharmacokinetics (PK) and confirm the dose of LDV/SOF 
FDCin chronic HCV -infected
pediatric subjects
The secondary objective of the PK Lead -inPhase of this study  is:
To evaluate the safet y,tolerability , and antiviral activity of 10days ofdosingof 
LDV/SOF FDC in chronic 
HCV-infected pediatric subjects
The primaryobjective of the Treatment Phase of this study  is:
To evaluate the safet y and tolerability  of LDV/SOF FDC for 12 weeks in chronic 
HCV-infected pediatric subjects
The secondary  objective sof the Treatment Phase of this study  are:
To determine the antiviral efficacy  of 12 weeks of LDV/SOF FDC treatment in chronic 
HCV-infected subjects (including the impact of 
HCV genot ype, IL28 genoty pe, and prior 
treatment experience) , as assessed b y the proportion of subjects with SVR 12 weeks after 
completion of treatment (SVR12)
To determine the antiviral efficacy  of 12 weeks of LDV/SOF FDC treatment in chronic
HCV-infectedsubjects, as assessed b y the proportion of subjects with SVR 4 and 
24
weeks after completion of treatment (SVR4 and SVR24)
To evaluate the kinetics of circulating HCV RNA during treatment and after completion
of treatment
To evaluate the emergence of vira l resistance to LDV and SOF during treatment and after 
completion of treatment
To evaluate the effect of growth and development on pediatric subjects during and after 
treatment
The exploratory  objective of this study  is:
  
 
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page25 10 July20143. STUDY DESIGN
3.1. Treatment Plan and Regimen
This is an o
pen-label, multi- cohort, two- part study evaluating the PK, safety, and antiviral 
activity of LDV/SOF FDC in chronic HCV -infected pediatric subjects.
3.1.1. PK Lead -in
The PK Lead-inPhasewill evaluate and/or confirm the age appropriate LDV/SOF FDC dose 
by analyzing PK, safety , and antiviral activit y of LDV/SOF FDC through 10days of dosing
for each cohort . Children aged 3 to < 6 years, children aged 6 to < 12 years,and adolescents 
aged 12 to < 18years with chronic HCV -infectionand aHCV RNA ≥1000 IU/mL  at study 
entry will be evaluated. Subjects must be treatment naïveto participate in the PK Lead-in
Phase. Threecohorts of at least10 subjects eachwill be sequentially enrolled: 
Cohort 1:   12 to < 18 y ears oldweighing ≥45kg
Cohort 2:   6 to < 12 y ears old 
Cohort 3:   3 to < 6 y ears old 
The study  will start with Cohort 1.  Subjects will receive LDV/SOF FDC (90 mg/400 mg 
adult tablet or 4 x22.5 mg/100mg tabletsif determined necessary based on LDV/SOF FDC
swallowability  assessment )for 10days with intensive PK conducted on Day  10. 
Following completion of study  treatment in the PK L ead-in of Cohort 1 and pending PK and 
safety results, the PK Lead- in of Cohort 2 will initiate and receive study  treatment (ag e 
appropriate dose and formulation). Following completion of study  treatment in the PK 
Lead-in of Cohort 2 and pending PK and safet y results, the PK L ead-in of Cohort 3 will 
initiate and receive study treatment (age -appropriate dose and formulation). 
Subjects enrolled in the PK Lead -in of each cohort (Cohorts 1, 2 and 3) will immediately  
enroll in the Treatment Phase as they  complete Day  10 of PK Lead- in.  They will continue 
dosing with LDV/SOF FDC with no interruption of study  drug administration.  Subjec ts 
rolling over from the PK Lead -in Phase will not be require d to perform the screening, Day 1,
or Week 1 visit of the Treatment Phase.
3.1.2. Treatment Phase
The Treatment Phase will be initiated sequentially by  age group as defined in Cohort 1, 2 ,
and 3 of the PK Lead-in. Subjects who participated in PK L ead-in will immediately  rollover 
into Treatment Phase with no interruption of study drug administration until the 
appropriateness of the dose has been confirmed b y PK and safety results from the PK 
Lead-in.  The first visit in the Treatment Phase for these subjects will be the Week 2 visit.  
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page26 10 July2014Additional subjects will be enrolled in the Treatment Phase of each Cohort upon 
confirmation of the appropriateness of the dose from the PK L ead-in.
Children aged 3 to < 12 years(Group 2) and adolescents aged 12 to < 18 years (Group1) 
with chronic HCV -infection and aHCV RNA ≥1000 IU/mL  at study entry (those who were 
dosed in the 
PK Lead- inwill have met this criteria prior to enrollment )will be evaluated.
Subjects enrolled in the Treatment Phase will receive the regimen of LDV/SOF FDC for 
12weeks.Subjects with GT 1 will be enrolled first.  If emerging LDV /SOFFDC data in 
GT-2, -4, -5, and -6 support treatment in these GT sin adults, pediatric subjects wit h 
GT-2, -4, -5, and -
6will be subsequentl y enrolled.  
The study  will enroll both treatment naïve and treatment experienced pediatric subjects with 
up to 4
0 subjects allowed to be treatment experienced . Approximately  200total subjects , 
including subjects from the PK Lead -inPhase, will be enrolled in the Treatment Phase as 
follows:
Group 1: 
Approximately  100adolescent subjects (12 to < 18 y ears of age)
Group 2: Approximately  100pediatric subjects (3 to < 12 y ears of age)
The following definitions will be used for treatment experienced subjects:
Interferon intolerant: Subject who discontinued therap y (≤ 12 weeks total) due to 
≥ 1adverse event
Interferon non- responder: Subject who did not achieve undetectable HCV RNA levels 
while on treatment
Relapse/breakthrough: Subject who achieved undetectable HCV RNA during treatment 
or within 4 weeks of the end of treatment but did not achieve a sustained virologic 
response (SVR)
All subjects who do not attain SVR or have viral relapse will be encouraged todiscuss 
treatment with SOCtherapy with their healthcare provider.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page27 10 July2014Figure3-1. Study Schema
3.2. Visit Schedule
3.2.1. PK Lead -in
Screening assessments will be completed within 28 days of the Day 1 visit. 
Study Visits will occur at Screening, Day  1, Day 3, and Day  10.
Subjects (at least10 subjects per cohort ) enrolled in the PK Lead-inPhasewill participate in 
an intensive PK evaluation on Day  10. Subjects will be administered a dosing diary with 
instructions.  
Following completion of the Day  10 intensive PK visit, s ubjects will then return for 
scheduled study visits outlined in the Treatment Phase and continuedosing with LDV/SOF 
FDCwith no interruption of study  drug administration .  Subjectsrolling over from the PK 
Lead-inPhasewill not be required to perform the Treatment Phase screening, Day  1,or 
Week 1 visits of the Treatment Phase .

LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page28 10 July20143.2.2. Treatment Phase
Screening assessments will be completed wi thin 28days of the Day  1 visit.Subjects 
continuing from the PK Lead -inPhasewill not be required to complete S
creening, Day 1,
and Week 1 visits of the Treatment Phase .
Study visits forall treatment phase subjectswill occur at S creening, 
Day 1, and the end of
weeks 1, 2, 4, 8, and 12. All subjects will then return for follow-up visits at 4 , 12,and 
24weeks after 
discontinuation of therapy.
The total time to complete all study  visits is approximately  40 weeks including:
28 day (4 week) screening period
12 
week treatment period
24 week post-treatment period
The assessments performed at each visit are described in Section 6.
3.3.
Virologic Response- Based Stopping Criteria
HCV RNA will be un
blinded to theInvestigator and Sponsor .
Thefollowing on -treatment virologic response- based treatment stopping criteria will be 
utilized:
Confirmed HCV RNA 
≥LLOQ after 2 consecutive HCV RNA <LLOQ
Confirmed >1 log 10  increase from nadir 
HCV RNA ≥LLOQ through 8 weeks of treatment
Confirmation should be performed as soon as possible but within 2 weeks after determination 
of initial observation .  Subjects that meet the virologic response- based stopping criteria 
above will be notified of their eligibility  to participate in the L ong-Term Follow -Up Study  
(GS-US-334-1113).
3.4. Treatment Discontinuations Criteria
The Medical Monitor should be consulted prior to subject discont inuation when medicall y 
feasible. Study medication mustbe discontinued in the following instances:
Unacceptable toxicity  (as defined in Section 7of the protocol
)or toxicity  that, in the 
judgment of the investigator, compromise s the ability  to continue study -specific 
procedures or is considered to not be in the subject’s best interest .
Pregnancy of female subject or female partner of male subject .
Efficacy failure as defined in Section3.3
.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page29 10 July2014Significant protocol violation including non -compliance with study  assessments.
Subject request to discontinue for an y reason; it is important to determine whether the 
withdrawal of consent is primarily  due to an AE, lack of efficacy ,or other reason.
Discontinuation of the study  at the request of Gilead, regulatory  agency,or an 
Institutional Review Board (IRB)/Independent Ethics Committee (I EC).
3.5. D iscontinuations
Subjects discontinuing treatment prior to completion of the assigned dosing period should 
complete an Early  Termination visit as described in the Section 6.4.5
.
Subjects who permanently discontinue thestudy drug for an y reason including safet y and/or 
tolerability  concerns prior to completion of the assigned dosing period will be followed 
according to the post
-treatment study  assessmentsdescribed in Section 6.5.
3.6. Pharmacogenomic Substudy
 
 
3.7. Long-Term Follow -Up
All subjects (those who attain SVR24 orthose who do not attain SVR24
) whodo not initiate 
other experimental or approved anti- HCV therapy will be followed every  
6 monthsfor 
assessments of growth, quality  of life, and long -term viral suppression (if applicable) in a 
separate protocol (GS-US-334-
1113). This follow -up study will continue for 5 y ears.
3.8. Breakthrough Futility Assessment
A futility assessment will be pe rformed after the first 10 subjects complete Week 8 on study  
or have viral breakthrough at or prior to Week 8. If 5 or more of the first 10 subjects enrolled 
have viral breakthrough at or prior to Week 8 or are non -responders (HCV RNA >LLOQ 
through 8 week s of treatment) then further enrollment of subjects will be 
suspended. Virologic breakthrough is defined as confirmed HCV RNA >LLOQ while on 
treatment after two consecutive visits with HCV RNA < LLOQ.
Subjects with known or suspected stud y drug non -adherence will not be considered to meet 
the definition of virologic breakthrough, relapse, or non-responder. 
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page30 10 July20144. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately 200subjects will be enrolled in this study .
In order to manage the total study enrollment, Gilead Sciences, Inc. at its sole discretion, may  
suspend screening and/or discontinue the enrollmen t at any site at any  time (upon written 
notice to the site). Discontinuation of the enrollment phase may  result in the immediate 
ineligibility of all subjects screened but not y et enrolled, regardless of the progress or 
outcome of the screening assessments performed.
4.2. Inclusion Criteria
Subjects must meet 
allof the following inclusion criteria to be eligible for participation in 
this study .
1.Parent or legal guardian able to provide written informed consent prior to any  screening 
evaluations and willing to comply  with study  requirements.  Subjects will provide assent 
if possible.
2. 3years to < 18 years of age as determined at Day  1 (consent of p arent or legal guardian 
required)
3.PK Lead-inonly: subjects in C ohort 1 (age 12 to <18 years of age) must weigh 45kg
4.PK Lead-in only: all subjects must be treatment naïve : no prior exposure to any  IFN, 
RBV, or other approved or experimental HCV- specificDAA agent
5.Treatment experience dsubjects:  prior treatment failure to a regimen including interferon 
either with or without RBV that was completed at least 8 weeks prior to Day 1.
i.Interferon intolerant: Subject who discontinued therap y (≤ 12 weeks total) due to 
≥ 1adverse event
ii.Interferon non- responder: Subject who did not achieve undetectable HCV RNA 
levels while on treatment
iii.Relapse/breakthrough: Subject who achieved undetectable HCV RNA during 
treatment or within 4 weeks of the end of treatmen t but did not achieve a 
sustained virologic response (SVR)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page31 10 July20146.Chronic HCV-infection documented b y either:
a)a positive anti- HCV antibody  test or positive HCV RNA or positive HCV genot yping 
test at least 6 months prior to the Day 1visit, or
b)a liver biopsy  performed prior to the Day 1visit with evidence of chronic HCV-
infection
7.Infection with HCV as determined at Screening .The study  will commence with GT -
1 
HCV-infected pediatric subjects and will subsequently  enroll subjects with GT-2, -4, -5 
and -6 once adult data is available, if appropriate. 
8.HCV RNA ≥ 1000 IU/mLat Screening
9.Adequate hematologic function (absolute neutrophil count 1,500/mm3; 
hemoglobin 11g/dL).
10.Negative serum -HCG pregnancy  test (for females of childbearing potential only, as 
defined in Appendix 5)
11.Subject able to provide written assent, if they have the ability  to read and write, as 
determined b y IRB/IEC/local req uirements and Investigator’s discretion
4.3. Exclusion Criteria
Subjects who meet 
anyof the following exclusion criteria are not to be enrolled in this study .
1.Pregnant or lactating subjects
2.Sexually-active males or females of childbearing potential who are not willing to use an 
effective method of contraception during the study (see Appendix 5for further details)
3. Decompensated liver disease defined as INR1.2ULN, platelets 50,000/mm3,
serum albumin 3.5g/dL, or prior history  of clinical hepatic decompensation 
(e.g.,ascites, jaundice, encephalopath y, variceal hemorrhage)
4. Chronic liver disease of a non- HCV etiology  (eg, hemochromatosis, Wilson’s disease, 
alpha-1 antitrypsin deficiency )
5.-fetoprotein 50ng/mL
6.Serum creatinine > 1.5 mg/dL
7.Estimated glomerular filtration rate 90mL/min/1.73m2, as calculated b y the Schwartz 
Formula
8. Evidence of hepatocellular carcinoma (HCC)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page32 10 July20149.Co-infection with HIV, acute HAV, or HBV
10.Significant cardiovascular, pulmonary ,or neurological disease
11.Evidence of a gastrointestinal malabsorption sy ndrome that may  interfere with absorption 
of orally administered medications
12.History of solid organ or bone marrow transplantation
13.Chronic daily  non-steroidalanti-inflammatory  drug therap y
14.Systemic corticosteroid use for  2 weeks(pulmonary /nasal administration is permitted)
15.Investigational agents taken within the past 28days(except with the expressed approval 
of the Sponsor)
16.Clinically -relevant alcohol or drug abuse within 12 months of screening.  A positive drug 
screen will exclude subjects unless it can be explained by  a prescribed medication; the 
diagnosis and prescription must be approved b y the investigator
17.Known hy persensitivity  to the study  drugs, th
e metabolites, or formulation excipients
18.Any other condition (including alcohol or substance abuse) or prior therapy  that, in the 
opinion of the I nvestigator, would make the subject unsuitable for the study  or unable to 
comply with dosing requirements
19.Use of an y prohibited concomitant medications as described in Section5.4within 
28days of the Day  1 visit
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page33 10 July20145. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomiz ation and Blinding
Not applicable .
5.2. Ledipasvir /Sofosbuvir Fixed-Dose Combination
5.2.1. Description and Handling 
5.2.1.1. Formulation
LDV/ SOF FDC tablets are orange, diamond -shaped, film -coated tablets containing 90 mg of 
LDV and 400 mg of SOF. The tablets are debossed with “GSI” on one side and “7985” on 
the other side. The LDV/SOF FDC tablets contain the following inactive ingredients: lactose 
monohydrate, copovidone, microcry stalline cellulose, croscarmellose sodium, colloidal 
silicon dioxide, magnesium stearate, pol yvinyl alcohol, titanium dioxide, talc, poly ethylene 
glycol, FD&C yellow # 6 /sunset y ellow FCF aluminium lake.
Placebo to match LDV/SOF FDC 90 mg/ 400 mg tablets for Swallowability  Assessment are 
orange, diamond -shaped, film -coated tablets debossed with “G SI” on one side and “7985” on 
the other side. The tablets contain lactose monoh ydrate, copovidone, microcry
stalline 
cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, pol yvinyl 
alcohol, titanium dioxide, talc, poly ethylene glycol, FD&C yellow # 6 /sunset yellow FCF 
aluminium lake.
Age-appropriate formulations of L DV/SOF FDC are currentl y under development which 
includes a lower dose strength tablet (LDV/SOF FDC 22.5 mg/ 100 mg) and a non -tablet 
formulation. The formulation and composition will be reflected in a protocol amendment 
which will be submitted for approval prior to dosing subjects who are unable to swallow the 
LDV/SOF FDC 90 mg/ 400 mg tablets.
Placebos to match LDV/SOF FDC 22.5 mg/ 100 mg tablets for Swallowability  Assessment 
are currentl y under development. The formulation and composition will be available and 
reflected in a protocol amendment which will be submitted for approval prior to dosing 
subjects who are unable to swallow the LDV/SOF FDC 90 mg/ 400 mg tablets.
The non-tablet LDV/SOF FDC formulation will be based on the PK results obtained from 
cohorts 1 and/or 2 of this study . The formulation, composition, acceptability (including 
palatability ) will be available and reflected in a protocol amendment which will be submitted 
for approval prior to dosing subjects who are unable to swallow tablets .
LDV/SOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
5.2.1.2. Packaging and Labeling Final 
Original 
LDV I SOF FDC 90 mg/ 400 mg tablets are packaged in white, high density polyethylene 
(HDPE) bottles. Each bottle contains 28 or 30 tablets, a silica gel desiccant, and polyester 
packing material. Each bottle is enclosed with a white, continuous thread, child resistant 
screw cap with an induction-sealed, aluminum faced liner. 
Placebo tablets to match LDV /SOF FDC 90 mg/ 400 mg tablets for Swallowability 
Assessment are packaged in white, high density polyethylene (HDPE) bottles. Each bottle 
contains 30 tablets, a silica gel desiccant and polyester packing material. Each bottle is 
enclosed with a white, continuous thread, child resistant screw cap with an induction-sealed, 
aluminum faced liner. 
The packaging and labeling of LDV /SOF FDC 22.5 mg/1 00 mg tablets will be based on the 
chosen formulation. The packaging and labeling will be available and reflected in a protocol 
amendment which will be submitted for approval prior to dosing subjects who are unable to 
swallow the LDV /SOF FDC 90 mg/ 400 mg tablets. 
The packaging and labeling ofthe placebo to match LDV/SOF FDC 22.5 mg/100 mg will be 
based on the chosen formulation. The packaging and labeling will be available and reflected 
in a protocol amendment which will be submitted for approval prior to dosing subjects who 
are unable to swallow the LDV /SOF FDC 90 mg/ 400 mg tablets. 
The packaging and labeling ofthe non-tablet LDV/SOF FDC formulation will be based on 
the chosen formulation. The packaging and labeling will be available and reflected in a 
protocol amendment which will be submitted for approval prior to dosing subjects who are 
unable to swallow tablets. 
All LDV/SOF FDC and placebo to match LDV/SOF FDC bottles to be distributed in the US, 
EU, and the rest ofthe countries shall be labeled to meet all applicable requirements ofthe 
US Food and Drug Administration (FDA), Annex 13 of Good Manufacturing Practices: 
Manufacture of investigational medicinal products (February 20 10), and/or other local 
regulations as applicable. 
5.2.2. Storage and Handling 
LDV I SOF FDC tablets, 90 mg/ 400 mg, should be stored at controlled room temperature 
until required for administration. Controlled room temperature is defined as 25 oc (77 °F); 
excursions are permitted between 15 DC and 30 DC (59 °F to 86 °F). 
Placebo to match Ledipasvir (LDV)/Sofosbuvir (SOF) FDC tablets, 90 mg/ 400 mg, for 
Swallowability Assessment should be stored at controlled room temperature until required 
for administration. Controlled room temperature is defined as 25 DC (77 OF); excursions are 
permitted between 15 DC and 30 DC (59 OF to 86 OF). 
CONFIDENTIAL Page 34 10 July 2014 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page35 10 July2014The storage and handling of the LDV/SOF FDC 22.5 mg/ 100 mg tablets and placebo to 
match LDV/SOF FDC will be bas ed on the chosen formulation. The storage and handling 
will be available and reflected in a protocol amendment implemented prior to dosing subjects 
who are unable to swallow the LDV/SOF FDC 90 mg/ 400 mg tablets.
The storage and handling of the non- tablet LDV/SOF FDC formulation will be based on the 
chosen formulation. The storage and handling will be available and reflected in a protocol 
amendment implemented prior to dosing subjects who are unable to swallow tablets.
All drug products should be stored in a securely locked area, accessible only to authorized 
site personnel. To ensure the stability  of the Investigational Medicinal Product (IMP) and to 
ensure proper product identification, the drug product should not be stored in a container 
other than the container in which they  are supplied. Consideration should be given to 
handling, preparation, and disposal through measures that minimize drug contact with the 
body. Appropriate precautions should be followed to avoid direct ey e contact or exposure 
through inhalation when handling LDV/SOF FDC.
Sufficient quantities of LDV/SOF FDC tablets, non
-tablet LDV/SOF FDC formulation, and 
placebo tablets will be shipped to the investigator or qualified designee from Gilead Sciences 
Materials & Logistics (or its designee ).
5.2.3. Dosage and Administration of L DV/SOF FDC
PK Lead-in: (Cohort 1) LDV /SOFFDC 90mg/ 400 mg tablet swillbe administered once 
daily with or without food. Subjects determined unable to swallow the placebo to match the 
90 mg/ 400 mg LDV/SOF FDC tablet (by  LDV/SOF FDC Placebo Swallowability  
Assessment at Screening up to Day  1) will be re -assigned to 4 x 22.5 mg/ 100 mg tablets 
daily.  Subjects who weigh < 45 kg will be excluded.
Intensive PK and safet y results from the PK Lead-i n of each Cohort will be review
ed to 
confirm the appropriateness of the evaluated LDV/SOF FDC dose for the Treatment Phase of 
that Cohort as well as to determine the age -appropriate dose to be evaluated in the PK 
Lead-in of the next Cohort.
Treatment Phase : Subjects who participated in the PK L ead-in of each Cohort will continue 
in the Treatment Phase with no interruption of study  drug administration until the 
appropriateness of the dose is confirmed b y PK and safet y data from the PK -Lead-in.  
Additional subjects will be enrolled in the Treatment Phase of each Cohort upon 
confirmation of the appropriateness of the dose.  
An additional age -appropriate formulation for LDV/SOF FDC Oral Granulates 
is currently  
under development. The dosefor this formulation will be dependent o n the PK results 
obtained from C ohorts 1 and/or 2 of this study . The strength, composition, and dosing 
administration will be available and reflected in a protocol amendment which will be 
submitted for approval prior to dosing subjectswho are unable to swallow tablets.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page36 10 July2014For missed dose(s) of study  medication, subjects should be instructed to take the missed 
dose(s) of IMP as soon as possible during the same day .  Subjects should be cautioned never 
to double the next dose with a missed dose of IMP under an y circumstances.
5.3. Study Drug Compliance
Subjects will be instructed to return an y unused LDV/SOF FDC in the original container on 
Day 10 (PK Lead-in) and/or at study  treatment visits every  4 weeks (Treatment Phase ) .  
Returned medication will be reconciled b y the investigator in order to monitor the subject’s 
compliance with the medication regimen.
5.4. Prior and Concomitant Medications
Concomitant medications taken within 30 day s prior to screening, up to and including 
30days after the last dose of study  drug, need to be recorded in the source documents and 
electronic case report form(s) (eCRFs).
The following medications are prohibited during the screening period and for a minimum of 
28days prior to the Day 1 visit through the end of treatment:
Hematologic stimulating agents (e .g
., erythropoiesis- stimulating agents (ESAs); 
granulocy te colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
Chronic use of s ystemic immunosuppressants for reasons other than kidney  graft 
maintenance including , but not limited to, corticosteroids ( prednisone equivalent of 
>10mg/day for > 2 weeks), azathioprine, or monoclonal antibodies (e .g., infliximab)
Investigational agents or devices for an y indication
Concomitant use of certain medic ations or herbal/natural supplements (inhibitors or inducers 
of drug transporters ie, P -gp) with study  drug(s) may  result in PKinteractions resulting in 
increases or decreases in exposure of study  drug(s). Examples of representative 
medications which are prohibited from 21 days prior to Day 1 through the end of 
treatment are listed below :
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page37 10 July2014Table5-1. Disallowed and Concomitant Medications to be Used with Caution
Drug Class Agents Disallowed Use with Caution
Acid Reducing 
AgentsaProton-Pump Inhibitors , H2-Receptor 
Antagonists , Antacids
AntiarrhythmicsbQuinidine
Anticonvulsantsc Phenobarbital, Phenytoin, 
Carbamazepine, Oxcarbazepine
AntimycobacterialscRifabutin, Rifapentine, Rifampin
Cardiac Medicationsb Digoxin, Valsartan, Olmesartan, 
Telmisartan, Ranolazine, Bosentan
Herbal/Natural 
SupplementscSt. John’s Wort, Echinaccea, Milk thistle 
(i.e., silymarin), Chinese herb sho -saiko-
to (or Xiao -Shai-Hu-Tang)
HMG-CoA Reductase 
Inhibitorsd RosuvastatinAtorvastatin, Simvastatin, Pravastatin, 
Pitavastatin, Fluvastatin, Lovastatin
a It is recommended to separate antacid and LDV/SOF administration by 4 hours. H2-receptor antagonists may be 
administered simultaneously with or staggered from LDV/SOF at a dose that does not exceed doses comparable to 
famotidine 40 mg twice daily.  Proton-pump inhibitor doses comparable to omeprazole 20 mg can be administered 
simultaneously with LDV/SOF or up to 2 hours after taking LDV/SOF. Proton -pump inhibitors should not be taken 
before LDV/SOF. 
bMay result in an increase in the concentration of study drugs and/or concomitant medications. Coadministration of 
LDV/SOF with digoxin may increase the concentration of digoxin. Caution is warranted and therapeutic concentration 
monitoring of digoxin is recommended when coadministered with LDV/SOF. 
cMay result in a decrease in the concentrations of study drugs.
dUse with study drugs may result in an increase in the concentration of the HMG -CoA Reductase Inhibitors. Monitor for 
signs and symptoms of muscle weakness or myopathy, including rhabdomyolysis.
Medicatio ns for disease conditions excluded from the protocol (e.g., active cancer, 
transplantation) are not listed under this Concomitant Medication section and are disallowed 
in the study .
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page38 10 July20146. STUDY PROCEDURES
All subjects will complete screening, on- treatment ,and post-treatment assessments. 
Screening assessments will be completed within 28 days of the Day  1 visit. The end of stud y 
will occur at the 24 -week Post -Treatment visit. The schedule of assessments is described 
below. 
Information on the specific laboratory  parameters to be measured and clinical assessments to 
be performed are provided in 
Section6.6.
6.1. Subject Enrollment 
Each candidate’s parent or legal guardian must sign an Informed Consent Form prior to the
conduct of an y screening procedures. Each study  candidatewho has the ability  to read and 
writemust sign an Assent Form, as required b y IRB/IEC/local requirements , prior to the 
conduct of an y study procedures . Screening evaluations will be used to determine the
eligibility  of each candidate for study enro llment. Candidates who fail to meet eligibility
criteria by screening evaluations may  be re-screened once ≥ 30days after the initial screen if
there is a reasonable expectation that the candidate will be eligible after repeat screening.
6.2. Screening Assessme nts
6.2.1. Screening Visit (Day –
28 to Day 0)
Subjects will complete all screening assessments within 28 days of the Day 1 visit.The 
screening window can be extended to 42 days for subjects requiring additional HCV GT
testing or for extenuating circumstances.
The following procedures will be performed and documented:
Written informed consent from parent or legal guardian and assent from subject, if
applicable (see above)
Medical history , including :
— Hepatitis C history
— Hepatitis C treatment history
— Family history, including height and weight of parents
— Liver biopsy  results (if available)
Complete phy sical examination 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page39 10 July2014Vitalsigns (temperature, blood pressure, pulse, respiratory  rate)andbody weight and 
height
Obtain blood samples for tests as listed in Section 6.6.1:
—Hematology
—Chemistry
—Coagulation tests
—HCV RNA
—Determination of HCV viral GT and subtype
—HCV antibody , HIV 1/2 antibody , and HBs antigen, HA Vantibody
—HbA1c
—TSH
—IL28B
—Serum-hCG pregnancy test for females of childbearing potential onl y
—Alpha fetoprotein (AFP)
— Alpha-1 anti-trypsin(ATT)
Obtain urine sample for:
—Urinalysis
—Urine Drug Screen
Review of concomitant medications
Ask subject and/or parent/legal guardian if the subject is able to swallow and tolerate 
taking pills.
Review of all inclusion and exclusion criteria
Perform LDV/SOF FDC swallowability  assessment 
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to 
the clinic for the Day 1 visit assessment s.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page40 10 July20146.3. PK Lead -in: Treatment Assessments 
6.3.1. Day 1 Visit
After confirmation of eligibility has been evaluated, t he following tests and procedures must 
be completed prior to enrollment and dosing/dispensing on Day 1:
Perform complete ph ysical examination
Tanner Pubertal Stage Assessment
Vital signs, including b ody weightand height measurements
A single X -ray of the left wrist, hand, and fingers for Bone Age Assessment
Assessment of AE
s and concomitant medications
Pregnancy  prevention counseling including partner pregnancy  prevention for male 
participants ( all subjects ≥ 12 years of age andsubjects < 12 y ears of age at the discretion 
of the Investigator based on subject’s pubertal stat us)
Obtain blood samples for:
—Hematology
—Chemistry
—Coagulation tests
—HCV RNA
—Viral 
sequencing (archive)
—  
 
Obtain urine samples for the following procedures:
—Urinalysis
—-hCG pregnancy  test for females of childbearing potential only
Subject completes quality of life survey : Subject is to review questionnaire witha
parent/guardian and write/mark answers directly onto the questionnaire .
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page41 10 July20146.3.1.1. Drug Administration
Dispense study  drug as directed by  the IWRS
Instruct the subject on the packaging, stora ge and administration of study  drug
Perform LDV/SOF FDC swallowability  assessment (for subjects administered LDV/SOF 
FDCin tablet form onl yif not previously  completed at screening ).  Observe the subject 
taking the first dose of study
 drug (with or withou t food) and record the time of first dose
Subjects will be administered a dosing diary
 with instructions.
6.3.2. Day 3
The following procedures/assessments are to be completed on Day 3:
Perform a s ymptom-directed physical examination as needed
Vital signs, including body weight and height
Assessment of AEs and concomitant medications
Review medication compliance with subject and/or subject’s 
parent/guardian
Obtain blood samples for:
—Hematology
—Chemistry
—HCV RNA
— Viral sequencing (archive)
Review subject dosi ng diary
6.3.3. Day 10 –Intensive PK 
The Day 10 Intensive PK visit should occur on the protocol -specified visit date based on the 
Day1 visit. For the purposes of scheduling, the Day  10 Intensive PK visit may  
beperformed within +3days of the protocol -specified visit dat e(subjects will continue daily  
dosing through the Intensive PK Visit).
Subjects should come in a fasted state for the Day 10
Intensive PK visit (i .e., no food or drink 
except water at least 8 hours prior to the Day 10 Intensive PK visit). 
Subjects and/or 
parents/guardians should be instructed that the Day 10dose of LDV/SOF FDC must notbe 
taken until the evaluations listed below are completed. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page42 10 July2014If the subject has alread y dosed prior to the Day 10clinic visit or is not in a fasted state, the 
Day10 intensive PK assessments must not be completed. The subject and/or 
parents/guardians should be instructed to return in a fasted state within 3days (Day s
11, 12, 
or 13)for the intensive PK visit. 
If dosing non -compliance is identified as per subject dosing diary  and pill count on or prior to 
the Day10visit, the Day 10intensive PK assessments must not be completed. The subject 
and/or parents/guardians should be counsel ed regarding proper dosing and be scheduled to 
return for the Day  10intensive PK visit no sooner than 3 day s following compliant dosing 
and no later than Day 14(i.e., return on Day 13or Day14).  If dosing non -compliance is due 
to an AE, consultation with the Gilead Medical Monitor is required regarding the potential of 
rescheduling the Day 10intensive PK visit.
In both scenarios described above, the subject and/or parents/guardians should be reminded 
not to take the LDV/SOF FDC prior to arriving at the clinic o n the day of the re-scheduled 
intensive PK vis it. All Day10 intensive PK assessments listed below should be completed 
when the subject returns.
The following evaluations are to be completed at the Day 10 Intensive PK visit:
Perform a s ymptom-directed physical examination 
Vital signs, including body  weight and height
Assessment of AEs and concomitant medications
Perform study  drug accountability  
Review Subject Dosing Diary
Review medication compliance with subject and/or parent/guardian.
Obtain urine samples for the following procedures:
—Urinalysis
— Urine pregnancy  test (females of childbearing potential only ). If the urine pregnancy  
test is positive, theIntensive PK sampling will not be completed. The positive result 
will be confirmed with a serum pregnancy  test. 
Obtain blood samples for the followi ng laboratory  analyses:
— Hematology  
—Chemistry  
—Coagulation tests
—HCV RNA
—
Viral sequencing (archive)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page43 10 July2014Perform intensive PK sampling: 
—Blood samples will be collected at 0 (predose, ≤30minutes prior to dosing). After 
collection of the predose sample, subjects will be provided a standardized meal. 
Within 5 minutes after consuming the standardized meal , subjects will be dosed with 
LDV/SOF FDC per dosing requirements.
—Post-dose blood samples will be collected as follows: 
For Cohorts 1 and 2 :  0.5, 1, 2, 3, 4, 5, 
8, and 12 hours post -dose (with predose 
also serving as t= 24).
For Cohort 3 only:
0.5, 2, 4, 8, and 12 hours post -dose (with predose also serving 
as t=24).
—Subjects will be restricted from food intake until after collection of the 4-hourpost 
dose blood sample , except for subjects in Cohort 3 .
Please also refer to the PK 
manual for details about standardized meals and PK sample processing instructions.
After completing the Day 10intensive PK visit subjects 
will then continue to the Week 2
visit in Treatment Phase (described in Section 6.4.2) with no interruption in dosing.
6.4. Treatment Phase : Treatment Assessments 
6.4.1. Day 1 Visit
After confirmation of eligibility has been evaluated, t he following tests and procedures must 
be completed prior to enrollment and dosing/dispensing on Day 1:
Perform complete ph ysical examination
Tanner Pubertal Stage Assessment
Vital signs, including body weight and height measurements 
A single X-ray of the left wrist, hand, and fingers for Bone Age Assessment
Review of AEs and concomitant medications
Pregnancy  prevention counseling including partner pregnancy  prevention for male 
participants ( all subjects ≥ 12 years of age andsubjects < 12 y ears of age at the discretion 
of the Investigator based on subject’s pubertal status)
. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page44 10 July2014Obtain blood samples for:
—Hematology
—Chemistry
—Coagulation tests
—HCV RNA
—Viral sequencing (archive)
—  
 
Obtain urine sample for:
—Urinalysis
—-hCG pregnancy  test for females of childbearing potential only
Subject completes quality of life survey: Subject is to review questionnaire witha
parent/guardian and write/mark answers directly onto the questionnaire
Perform LDV/SOF FDC swallowability  assessment (for subjects administered LDV/SOF 
FDCin tablet form onl y if not previously completed at screening) 
6.4.1.1. Drug Administration
Dispense study  drug as directed by  the IWRS
Instruct the subject on the packaging, storage ,and administration of study drug
Observe the subject taking the first dose of study  drug (with 
or without food) and record 
the timeof first dose
6.4.2. Weeks 1 and 2(3 days)
Subjects who participated in the PK L ead-in will start study  visits in the Treatment Phase at 
Week 2.  The following procedures/as sessments are to be completed at these visits :
Vital signs, including b ody weightand height measurements 
Perform sy mptom-directedphysical examination
Assessment of AEs and concomitant medications
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page45 10 July2014Obtain blood samples for:
—Hematology
—Chemistry
—Coagulation tests
—HCV RNA
— Viral sequencing (archive)
—Single PK 
6.4.3. Weeks 4 and8 (3 days)
Vital signs, including b ody weightand height measurements 
Perform sy mptom-directedphysical examination
Assessment of AEs and concomitant medications
Obtain blood samples for
—Hematology
—Chemistry
—Coagulation tests
—HCV RNA
—Viralsequencing (archive)
—Single PK 
Obtain urine sample for:
—-hCG pregnancy  test for females of childbearing potential only
Review medication compliance with subject and/or parent/guardian (subject should 
return all study  drugs at these visits)
Dispense study  drug as directed by  
the IWRS
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page46 10 July20146.4.4. Week 12 ( 3 days)
Perform complete ph ysical examination
Tanner Pubertal StagingAssessment
Vital signs, including b ody weightand height measurements
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling including partner pregnancy  prevention for male 
participants ( all subjects ≥ 12 years of age andsubjects < 12 y ears of age at the discretion 
of the Investigator based on subject’s pubertal status)
Obtain blood samples for:
—Hematology
—Chemistry
—Coagulati ontests
—HCV RNA
—Viral 
sequencing (archive)
—TSH
—Single PK 
Obtain urine sample for:
—-hCG pregnancy test for females of childbearing potential only
Subject completes quality of life survey : Subject is to review questionnaire witha
parent/guardian and writ e/mark answers directly onto the questionnaire .
Review medication compliance with subject and/or parent/guardian.
Subjects should return all bottles of study drug at the Week 12 Visit
6.4.5. Unscheduled Visit/Early Termination Visit
A subject should attend an unscheduled visit if requested by  the sponsor or the investigator. 
The assessments are at the investigator’s discretion.
The Sponsor/CRO should be informed when a subject comes off treatment due to an adverse 
event. If a subject discontinues treatment the n the assessments outlined below should be 
performed.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page47 10 July2014Perform complete ph ysical examination
Tanner Pubertal StageAssessment
Vital signs, including b ody weightand height measurements
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling including partner pregnancy  prevention for male 
participants ( all subjects ≥ 12 years of age andsubjects < 12 y ears of age at the discretion 
of the Investigator based on subject’s pubertal status)
Obtain blood samples for:
—Hematology
—Chemistry
—Coagulation tests
—HCV RNA
—Viral 
sequencing (archive)
—TSH
—Single PK 
Obtain urine sample for:
—-hCG pregnancy test for females of childbearing potential only
Subject completes quality of life survey : Subject is to review questionnaire witha
parent/guardian and write/mark answers directly onto the questionnaire .
Review medication compliance with subject and/or parent/guardian.
Subjects should return all bottles of study drugat the Earl y Termination Visit
All subjects should complete Post- Treatment assessments after early termination, as 
described in 
Section6.5.
Subjects who do not attain SVR24 and do not initiate exper imental or approved anti -HCV 
therapy will be followed every 6 months for assessments of growth, quality of life, and 
long-term viral suppression (if applicable) in a separate protocol (GS- US-334-1113). This 
follow-up will continue for 5 y ears.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page48 10 July20146.5. Post-Treatment Assessments
6.5.1. 4- Week Post -Treatment Visit ( 5 days)
Vital signs, including b ody weightand height measurements 
Perform sy mptom-directedphysical examination
Assessment of AEs and concomitant medications
Obtain blood samples for: 
—Hematology
—Chemistry
—HCV RNA
—Viral sequencing (archive)
Obtain urine sample for:
—-hCG 
pregnancy test for females of childbearing potential only
Pregnancy  prevention counseling including partner pregnancy  prevention for male 
participants ( all subjects ≥ 12 years of age andsubjects < 12 years of age at the discretion 
of the Investigator based on subject’s pubertal status ) 
6.5.2. 12- Week Post -Treatment Visit ( 5 days)
Vital signs, including b ody weightand height measurements
Perform s ymptom-directed phy sical examination
Assessment of S AEs
Perform Tanner Pubertal Stage assessment
Obtain blood samples for 
—Hematology
—Chemistry
—HCV RNA
—Viral sequencing (archive)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page49 10 July2014Obtain urine sample for:
—-hCG pregnancy  test for females of childbearing potential only
Pregnancy  prevention counseling including partner pregnancy  prevention for male 
participants ( all subjects ≥ 12 years of age andsubjects < 12 y ears of age at the discretion 
of the Investigator based on subject’s pubertal status)
Subject completes quality of life survey : Subject is to review questionnaire with a 
parent/guardian and write/mark answers directly onto the questionnaire
6.5.3.
24-Week Post -Treatment Visit ( 5 days)
Vital signs, including b ody weightand height measurements 
Perform sy mptom-directedphysical examination
Assessment of S AEs
Tanner Pubertal StageAssessment
A single X -ray of the left wrist, hand, and fingers for Bone Age Assessment
Obtain blood samples for 
—HCV RNA
—
Viral sequencing (archive)
Subject completes quality of life survey : Subject is to review questionnaire with a 
parent/guardian and write/mark answers directly onto the questionnaire .
All subjects (those who attain SVR24 or those who do not attain SVR24) who do not initiate 
other experimental or approved anti -HCV therapy will be followed every  6months for 
assessments of growth, quality  of life, and long -term viral suppression (if applicable) in a 
separate protocol (GS -US-334-1113). This follow- up will continue for 5 years.
6.6. Procedures and Specifications
6.6.1. Clinical Laboratory Analytes
Hematology :Hematocrit, Hemoglobin (Hb), Plate let count, Red blood cell count (RBC), 
White blood cell count (WBC) with differential (absolute and percentage) including 
Lymphocytes, Monocy tes, Neutrophils, Eosinophils, Basophils, Reticulocy te count and 
MCV.
Coagulation : INR, Prothrombin time (PT), Activa ted partial thromboplastin time (APTT) 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page50 10 July2014Chemistry Alanine aminotransferase (ALT/SGPT), Aspartate aminotransferase 
(AST/SGOT), Albumin, Alkaline phosphatase, Creatinine, Total Bilirubin (reflex to Direct 
Bilirubin), Gluc ose, Lipase, Potassium, Sodium, Gamma -glutamyl transferase (GGT), alpha 
fetoprotein (AFP), alpha -1 anti-trypsin, creatine kinase (CK) and amylase.
Urinalysis:Appearance, Blood, Color, Glucose, Leukocy te esterase, pH, Protein, 
Urobilinogen. R eflex to micr oscopic urinal ysis if dipstick result is abnormal.
Virological Tests: Serologies for HCV, HBV and HIV. HCV RNA will be measured using 
the COBAS®AmpliPrep/COBAS®TaqMan®HCV Test , v2.0 for Use with the High Pure 
System. HCV GT and subty pe will be determined using the Sie mens VERSANT®HCV 
Genotype INNO-LiPA 2.0 Assay. Gilead reserves the right to use alternate assay s for HCV 
RNA and HCV GTshould the above assay s become unavailable.
IL28B genoty pe will be determined by  polymerase chain reaction (PCR
) amplification of the 
SNP, rs12979860, with sequence specific forward and reverse primers and allele specific 
fluorescentl y labeled TaqMan®MGB probes. Gilead reserves the right to use alternate assay s 
for IL28B determination should the above assay  becomeunavailable.
Pregnancy  Tests: Serum  -hCG, Urine -hCG (if positive, requires immediate confirmation 
with Serum -hCG)
Additional Tests : Urine Drug Screen (for amphetimines, cocaine, methadone, opiates), 
Hemoglobin A1c (HbA1c) ,TSH(reflex Free T4),Alfa fetoprotein (AFP), Alpha -1 
anti-trypsin(AAT).
6.6.2. Medical History
Medical history  including details regarding illnesses and allergies, date(s) of onset, and 
whether condition(s) is currently ongoing, and medication history will be collected on all 
subjects during screening. Parental heights will be recorded at Day 1.
6.6.3. Complete Physical Examination
A complete ph ysical examination must include source documentation of general appearance, 
and the following bod y systems: Head, neck and thy roid; eyes, ears, nose, t hroat, mouth and 
tongue; chest (excluding breasts); respiratory; cardiovascular; l ymph nodes, abdomen; skin, 
hair, nails; musculoskeletal; neurological. 
6.6.4. Tanner Pubertal StageAssessment
The Tanner Stage scale is available in Appendix 4
.  All subjects will receive a baseline 
Tanner Pubertal Stage Assessment. If the assessment determines that the subject is at a 
Tanner 5 at Day 1, no further Tanner Pubertal Stage Assessments are to be completed . Date 
of first menses will be documented. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page51 10 July20146.6.5. Height & Weight Measu rement
Height and weight measurement will be collected at each stud y visit.The difference in bod y 
weight and height measurements between Day 1 andEnd ofTreatment, post -treatment 
Week12, and post -treatment Week 24 will be calculated.  
6.6.6. Bone Age Assessme nt
A single X -ray of the left wrist, hand, and fingers will be performed at Day 1 Visit and 
post-treatment Week 24 .  
Local radiologist to determine bone age from x -ray.
6.6.7. Swallowability Assessment
ALDV/SOF FDC swallowability assessment will be performed at 
screening up to Day  1.  
Subjects who have indicated that they  can take pills will be observed taking a placebo to 
match the 90 mg/ 400mg LDV/SOF FDC tablet. This will 
confirm the swallowability of the 
90 mg/400mgtablet size . Ifa subject is unable to s wallowthe 90mg/400mg LDV/SOF 
FDC tablet size ,he/she will repeat the assessment with a placebo for the 22.5 mg/ 100 mg 
LDV/SOF FDC tablet.If unable to 
swallowthe 22.5 mg/100mg LDV/SOF FDC tablet, 
enrollment of the subject will be deferred until the granule formulation is available.
6.6.8. Vital Signs
Assessment of vital signs will include measurement of resting blood pressure, pulse, 
respiratory  rate, and temperature.
Blood pressure will be measured using the following standardized process:
Subject should sit for 
5 minutes with feet flat on the floor and measurement arm 
supported so that the midpoint of the manometer cuff is at heart level;
Use a mercury  sphygmomanometer or automatic blood pressure device with an 
appropriatel y sized cuff with the bladder centered over the brachial artery ;
Measure and record the blood pressure to the nearest 2 mmHg mark on the manometer or 
to the nearest whole number on an automatic device.
6.6.9. Estimated Glomerular Filtration Rate (GFR)
Estimated Glomerular Filtration Rate (GFR) using Schwartz Formula (mL/min/1.73m2) = 
kL/Scr[(kis a proportionality  constant, for adolescent females ≥ 12 years old is 0.55; and 
for adolescent males ≥12years old is 0.70); L is height in centimeters (cm); and S cris serum 
creatinine (mg/dL)]
6.6.10. Viral Sequencing (Archive)
Plasma samples will be collected at Day 1and each subsequent visit for viral sequence 
analysis. Unused samples may  be archived.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page52 10 July20146.6.11. Pregnancy Testing
All females of childbearing potential will have urine pregnancy  testing every  4weeks during 
the dosing period and for a minimum of 30 day sfollowing the last dose of LDV/SOF FDC . If 
required b y local regulations, additional pregnancy tests beyond 3
0 daysmay be added. In 
the event of a positive urine pregnancy  result, subjects will be instructed to stop study  drugs 
immediately  (if applicable) and return to the clinic as soon as possible for a serum pregnancy  
test.
6.6.12. Quality of Life Survey (PedsQL™)
The PedsQL ™ Pediatric Quality  of Life Inventory V4.0 Short Form (SF15) will be 
completed in Treatment Phase of the stud y at Day 1, End of Treatment , 
Early Termination (if 
applicable) , 12-Week Post -Treatment ,and 24-Week Post -Treatment visits.   
The PedsQL ™  has separate survey  instruments administered by age group , including the
Teen Report (ages 13 -18), Child Report (ages 8-12), Young Child Report (ages 5- 7), and 
Toddlers (ages 2 -4).  Each survey  will be administered to the subject for the current age 
group at t he time of survey  administration.  
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page53 10 July20147. TOXICITY MANAGEMENT
7.1. Subject Stopping Rules for LDV/SOF FDC
The Gilead Medical Monitor should be consulted prior to dose discontinuation of LDV/SOF 
FDCunless the investigator believes that immediate action is warranted to ensure the 
continued safet y of the subject.
Administration of LDV/SOF FDC may be discontinued due to a clinical or laboratory  event. 
There is no option for LDV/SOF FDC dose reduction. If LDV/SOF FDC is stopped for 
toxicity, it should not be restarted .
Subjects who meet an y of the following laboratory criteria should stop treatment with 
LDV/SOF FDC :
Elevation of ALT and/or AST >5x Day 1or nadir, confirmed by  immediate repeat testing
Abnormal elevation of ALT >3x Day  1and total bilirubin >2 x UL N, confirm ed by 
immediate repeat testing
Confirmed e levation of AL T >15 x ULN, confirmed by  immediate repeat testing
Any Grade 3 or greater rash associated with constitutional sy mptoms
Any Grade 4 event 
or lab abnormality  assessed as related to treatment with LDV/SOF
FDC
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page54 10 July20148. ADVERSE EVENTS MANAG EMENT
8.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
8.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a pharmaceutical product, which 
does not necessaril y have a causal relationship 
with the treatment. An AE can therefore be an y unfavorable and/or unintended sign, 
symptom, or disease temporally  associated with the use of a medicinal product, whether or 
not considered re lated to the med icinal product. AEs may also include pre -or post-treatment 
complications that occur as a result of protocol-mandatedprocedures, overdose ,drug 
abuse/misuse reports, or occupational exposure
.Preexisting events that increase in severit y 
or change in natu re during or as a consequence of participation in the clinical study  will also 
be considered AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy ,tooth extraction, and 
transfusion. T he condition that ledto the procedure may  be an adverse event and must be 
reported
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before
the screening visit that donot worsen.
Situations where an untoward medical occurrence has not occurred (e.g., hospitalization 
for elective surgery , socialand/or convenience admissions).
Overdose without clinical sequelae (see Section 8.5)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not 
an AE. It is considered to be pre -existing and should be documented on the medical 
history CRF
8.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an
event that, at an y dose, results in the 
following :
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to 
an event in whic h the subject was at risk of death at the time of the event; it does not refer 
to an event that h ypothetically might have caused death if it were more severe.)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page55 10 July2014In-patient hospitalization or prolongation of existing hospitalization
Persistent or significant disability/incapacit y
A congenital anomal y/birth defect
A medically important eventor reaction: s
uch events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subjector may 
require intervention to preven t one of the other outcomes constituting SAEs. Medical and 
scientific judgment mustbe exercised to determine whether such an event is reportable 
under expedited reporting rules. Examples of m edically important e vents include 
intensive treatment in an emergency  room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospitalization; anddevelopment of drug 
dependency  or drug abuse. For the avoidance of doubt, infections res ulting from 
contaminated medicinal product will be considered a m edically important 
event and 
subject to expedited reporting requirements.
8.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections8.1.1and 8.1.2.If the laboratory  
abnormality is part of a sy ndrome, recor d the syndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
8.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event
information and assessments.
8.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to 
IMPtherapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the investigational 
medicinal product. For SAEs, an alternative causality  must be provided (e.g., pre -existing 
condition, underlying disease, intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product .
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page56 10 July2014It should be emphasized that ineffective treatment should not be considered as causall y 
related in the context of AE reporting.
The relationship to study  procedures (e.g., invasive procedures such as venipuncture or 
biopsy) should be assessed using the following considerations:
No:Evidence exists that the AE has an eti ology other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures (eg., venipuncture)
8.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3, or 4 using the GSI Grading 
Scale for Severity of Adverse Events and Laboratory  Abnormalities (Appendix 3
).
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of 
the clinical severit y in the context of the underl ying conditions; this may  or may not be in 
agreement with the grading of the laboratory  abnormality .
8.3. Investigator Requirements and Instructions for Reporting Adverse 
Events and Serious Adverse Events to Gilead or CRO
Requirements for collection prior to study  drug initiation:
After informed consent, but pr ior to initiation of study  medication, the following t ypes of 
events should be reported on the case report form (CRF/eCRF): all SAEs and adverse events 
related to protocol -mandated procedures.
Adverse Events
Following initiation of study  medication, collec t all AEs, regardless of cause or relationship, 
until 4 weeks after last administration of study  
drug must be reported to the CRF/eCRF 
database as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible.
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined 
follow up period.
Serious Adverse Events
All SAEs, regardless of causal relationship, that occur after the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required 24-week post treatment follow -up period, must be 
reported to the CRF/eCRF database and Gilead Drug Safety  and Public Health (DSPH) as 
instructed. This also inc ludes any SAEs resulting from protocol- mandated procedures
performed after informed consent is signed 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page57 10 July2014Any SAEs and deaths that occur after the post treatment follow -up visit but within 30 days of 
the last dose of study  IMP, regardless of causalit y, should also be reported . Investigators are 
not obligated to actively  seek SAEs after the24 week post
-treatment follow -up period.  
However, if the investigator learns of an y SAEs that occur after stud y participation has 
concluded and the event is deemed relevan t to the use of IMP, he/she should promptly  
document and r eport the event directl y to Gilead DSPH.  
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in 
the eCRF completion guideline.
Electronic Serious Adverse Event (e SAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the 
event. Detailed instructions can be found in the eCRF completi on guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the 
eCRF database is not functioning, record the SAE on the paper serious adverse event 
reporting form and submit within 24 hours to:
Gilead Sciences, 
Drug Safet y and 
Public Health :Fax:
E-mail:+1 650 522-5477
Safety_FC@gilead.com
PRA International
Pharmacovigilance 
Representative:Fax:
E-mail:+1 888 772 6919 (North America);
+49 621 8782 181 (Rest of World)
CHOSafet y@praintl.com
Gilead Sciences,
Medical Monitor:Name:
Phone:
Mobile:
Fax:
E-mail:Luisa Stamm , MD, PhD
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been 
locked, no further action is necessary .
All AEs and SAEs will berecorded in the CRF/eCRF database within the timel ines 
outlined in the CRF/eCRF completion guideline .
PPD
PPD
PPD
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page58 10 July2014For fatal or life -threatening events, copies of hospital case reports, autops y reports, and 
other documents are alsoto be submitted by e
-mail or fax when requested and applicable. 
Transmission of su ch documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate 
safety reports.
Any medications necessary  for treatment of the SAE must be recorded onto the 
concomitant medication section of the subject’s CRF/eCRF and the event description 
section of the SAE report form.
8.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA 
Code of Federal Regu lations, the EU Clinical Trials Directive (2001/20/EC) and relevant 
updates, and other country- specific legislation or regulations , Gilead may  berequired to 
expedite to worldwide regulatory  agenciesreports of SAEs , serious adverse drug reactions 
(SADRs)
,or suspected u nexpected serious adverse reactions (SUSARs). In accordance with 
the EU Clinical Trials Directive (2001/20/EC), Gilead or a specified designee will notify  
worldwide regulatory  agencies and the relevant IECin concerned Member States of 
applicable SUSARs as outlined in current regulations.
Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the i nvestigator’s b
rochureor relevant local label as applicable . 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports
associated with an y study IMP. The investigator should notify  the IRB or IEC of SUSAR 
reports as soon as is practical, where this is requ ired by local regulatory  agencies, and in 
accordance with the local institutional policy .
8.5. Special Situations Reports
8.5.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, and 
pregnancy reports regardless of an associated AE.  
Medication error is any unintentional error in the prescribing, dispensing ,or administration 
of a medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent orsporadic intentional excessive use of a medicinal product by  
a subject.
Misuse is defined as an y intentional and inappropriate use of a medicinal product that is not 
in accordance with the protocol instructions or the local prescribing information.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page59 10 July2014An overdose is defined as an accidental or intentional administration of a quantity  of a 
medicinal product given per administration or cumulatively  which is above the maximum 
recommended dose as per protocol or in the product labelling (as it applies to the daily  dose 
of the subject in question). In cases of a discrepancy  in drug accountability , overdose will be 
established only  when it is clear that the subject has taken the excess dose(s). Overdose 
cannot be established when the subject canno t account for the discrepancy  except in cases in 
which the investigator has reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the 
manufacture, packaging or distribution of the medicinal product.  
8.5.2. Instructions for Reporting Special Situations
8.5.2.1. Instructions for Reporting Pregnancies
The investigator should report all pregnancies that are identified after the sub ject 
firstconsents to participate in the study  (ie, signs the informed consent) and throughout the 
study, including the post -treatment follow-up period, to Gilead DSPH using the pregnancy  
report form within 24 hours of becoming aware of the pregnancy .
Refer to S ection8.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abort
ion to terminate 
a pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24hours 
as 
an SAE. The underly ing medical reason for this procedure should be recorded as the AE
term.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described 
in Sections8.1.1and 8.3. Furthermore, an y SAE occurring as an adverse pregnancy  outcome 
post study  must be reported directl y to Gilead DSPH .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead DSPHusing the pregnancy  outcome 
report form. If the end of the pregnancy  occurs after the study  has been completed, the 
outcome should be reported directl y to Gilead DSPH. Gilead DSPH c ontact information is as 
follows: Email: Safety _FC@gilead.com orFax: +1(650)522-
5477.
Pregnancies of female partners of male stud y subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using 
the pregnancy  report form and pregnancy  outcome report forms within 24 hours. Monitoring 
of the partner pregnancy should continue until the conclusion of the pregnancy . If the end of 
the pregnancy  occurs after the study  has been completed, the outcome should be reported 
directly to Gilead DSPH, fax number +1 (
650)522-5477 or email Safety_FC@gilead.com. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page60 10 July2014Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements.
8.5.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the 
situation. These reports must consist of situations t hat involve study  IMPand/or Gilead 
concomitant medications , but do not apply to non-Gilead 
concomitant medications. 
Special situations involving non-Gilead concomitant medications doesnot need to be 
reportedon the special situations report form; howeve
r, for special situations that result in 
AEs due to a non- Gilead concomitant medication, the AE should be reported on the AE 
form. 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection8.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or 
SAEs at the same time using the AE eCRF and/or the SAE report form. Details of the 
symptoms and signs, clinical management and outcome will be reported, when available.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page61 10 July20149. STATISTICAL  CONSIDER ATIONS
9.1. Analysis Objectives and Endpoints
9.1.1. Analysis O bjectives
The primary  objective of PK Lead-inPhase of this study  is:
To evaluate the stead y state pharmacokinetics (PK) and confirm the dose of LDV/SOF 
FDCin chronic 
HCV-infected
pediatric subjects
The secondary objective of PK Lead- inPhase of this study is:
To evaluate the safet y,tolerability , and viral activity of 10days ofdosingof LDV/SOF 
FDCin chronic HCV -infectedpediatric subjects
The primaryobjective of Treatment Phase of this study  is:
To evaluate the safet y and tolerability  of LDV/SOF FDC for 12 weeks in chronic 
HCV-infectedpediatric subjects
The secondary  objective sof Treatment Phase of this study  are:
To determine the antiviral efficacy  of 12 weeks of LDV/SOF FDC treatment in chronic 
HCV-infected subjects, as assessed b y the proportion of subjects with SVR 12 weeks 
after completion of treatment (SVR12)
To determine the antiviral efficacy  of 12 weeks of LDV/SOF FDC treatment in chronic 
HCV-infected subjects (including the impact of HCV genot ype, IL28 genoty pe and prior 
treatment experience ), as assessed b y the proportion of subjects with SVR 4 and 
24
weeks after completion of treatment (SVR4 and SVR24)
To evaluate the kinetics of circulating HCV RNA during treatment and after completion
of treatment
To evaluate the emergence of viral resistance to LDVand SOF during treatment and after 
completion of treatment
To evaluate the effect of growth and development on pediatric subjects during and after 
treatment
The exploratory  objective of this study  is:
  
 
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page62 10 July2014 
9.1.2. Primary Endpoint s
For the PK Lead -in Phase, AUC tauof GS-331007 and LDV areconsidered the primary  PK 
parameter s for determining the appropriate LDV/SOF FDC dose.
For the 
Treatment Phase , theprimary safety endpoint is any AE leading to permanent 
discontinuation of study  drug (s). The primary  efficacyendpoint is SVR12.
9.1.3. Secondary Endpoints
For the PK Lead -in Phase,the secondary  PK endpoints 
will includeearly viral kinetics and 
the following PK endpoints: AUCtau, Cmax, AUC last, Tmax, Clast, Tlast, Ctauand t1/2for 
GS-331007, SOF, and LDVas appropriate .AEsleading to permanent discontinuation of 
study drug(s)will be evaluated as a secondary  safety endpoint. Secondary  safety endpoints of
growth and development measurement s will beassessed (e .g.height, weight, and Tanner 
Stage Assessment )
.
For the Treatment Phase , secondary efficacy endpoints include SVR4, SVR24, breakthrough 
and relapse. Additional efficacy  evaluations may  include HCV R NA change from Day  1; 
ALT normalization; and viral kinetic parameters .
9.2. Analysis Conventions
All individual subject data will be listed as measured. All statistical summaries and anal yses 
will be performed using SASsoftware (SAS Institute, Cary, NorthCarolina, USA).
9.2.1. Analysis Sets 
9.2.1.1. Pharmacokinetics (PK) Analysis Sets
Intensive PK Analysis Set 
The intensive PK anal ysis set will include all PK Lead -insubjects who received at least one 
dose of study  drug and for whom at least one non-missing PK concentration data, during the 
intensive sampling period
,reported b y PK lab. The PK anal ysis set will be used for detailed 
pharmacokinetic anal ysis ofLDV, SOF, and metabolites.  
SparsePK Analysis Set 
The PK anal ysis set will include all enrolled subjectswho received at least one dose of stud y 
drug and for whom at least one ob served concentration data of LDV, SOF,or GS-331007 are 
available. The PK anal ysis set will be used for analy sis of general PK and single sample 
plasmaconcentrations.
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page63 10 July20149.2.1.2. Safety Analysis Set
The primary  analysis set for safety anal yses will include subjects who were enrolled and have 
received at least one dose of study  drug.
Treatment -emergent data will be anal yzed and defined as data collected from the first dose of 
study drug 
through the date of last dose of stud y drug plus 30 days.
9.2.1.3. Efficacy Analysis Set
The analysis set for antiviral activity anal yses will be the Full Anal ysis Set (FAS) which 
includes HCV-infected subjects who were enrolled and have received at least one dose of 
study drug.
9.2.2. Data Handling Conventions
Natural logarithm transformation for key  PK parameters, such as C max and AUC tau, will be 
applied for pharmacokinetic anal ysis.
The PK concentration values below the limit of quantitation (BLQ) will be treated as ze ro for 
the determination of summary  and order statistics. I ndividual values that are BLQ will be 
presented as “BLQ” in the concentration data listing and will be excluded in any  calculation 
of geometric means or ratios. For the presentation of summary  and order statistics, if at least 
1 subject has a concentration value BLQ for the time point, then the minimum value will be 
displayed as “BLQ”. If more than 50% of the subjects have a concentration data value BLQ 
for the time point, then the minimum and media n values will be display ed as “BLQ”. If all 
subjects have concentration data values BLQ for the time point, then all order statistics 
(minimum, first quartile [Q1], median, third quartile [Q3], maximum) will be displayed as 
“BLQ”.
Missing data can have an impact upon the interpretation of the trial data. Other than the 
endpoints discussed below, i n general, values for missing data will not be imputed. 
For the anal ysis of post-baseline categorical efficacy  endpoints, if a data point is missing and 
is preceded and followed in time by  values that are deem successes, then the missing data 
point will be termed a success; otherwise the data point will be termed a failure.
Any subject with missing data due to premature discontinuation of the study  medication will 
be considered a failure at the time points subsequent to the date of discontinuation. If no 
HCV RNA values are obtained after the last dose of study  medication, the subject will be 
considered a treatment failure for the SVR endpoints. 
Where appropriate, safety  data for subjects that did not complete the study  will be included in 
summary statistics. For example,
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page64 10 July2014If a subject received study  medication, the subject will be included in a summary  of 
adverse events according to the treatment received; otherwise, if the subject is not dosed 
then they will be excluded from the summary .
If safety laboratory  results for a subject are missing for any  reason at a time point, the 
subject will be excluded from the calculation of summary  statistics for that time point. I f
the subject is missing a pre- dose value, then the subject will be excluded from the 
calculation of summary  statistics for the pre -dose value and the change from pre -dose 
values.
Values for missing safety laboratory  data will not be imputed; however, a mis sing baseline 
result will be replaced with a screening result, if available. If no pre -treatment laboratory  
value is available, the baseline value will be assumed to b
e normal (i.e., no grade [Grade 0]) 
for the summary  of graded laboratory  abnormalities.
Values for missing vital signs data will not be imputed; however, a missing baseline result 
will be replaced with a screening result, if available.
HCV RNA values below the LLOQ for the assay  will be set to the lower limit minus 1 for 
calculation of summary statistics for the actual HCV RNA values and the change from 
baseline values b y study visit. The reported values will be provided in the HCV RNA listing.
For selected anal yses of early time point data, HCV RNA data (IU/mL) may be transformed 
to the logari thmic (base 10) scale (log 10IU/mL).
9.2.3. Interim Analysis
No formal interim anal yses are planned for this study .
9.3.
Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized using standard descriptive 
methods by  age group and overall for PK Lead -inand Treatment Phase respectivel y. 
Demographic data will include sex, self- identified race/ethnicity , and age.
Baseline characteristic data will include body  weight, height, body  mass index, HCV RNA 
level (log 10IU/mL), HCV GT , prior treatment experience, and additional endpoints as 
necessary .
9.4. Pharmacokinetic Analysis
PK analysis will be performed for PK Lead-inusing the i ntensive PK analy sis set. The 
concentration data of LDV, SOF , and metabolites (GS
-566500 and GS -331007)over 
sampling time will be listed and summarized by nominal time and cohort . Pharmacokinetic 
parameters (e.g., AUCtau, AUC last, Cmax, Tmax, Clast, Tlast, Ctau, λz, CL/F, Vz/F and t ½) will be 
listed and summarized for LDV, SOF ,  and metabolites (as applicable) using descriptive 
statistics (e.g., sample size, arithmetic mean, geometric mean and its 95% confidence 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page65 10 July2014interval, coefficient of variation %, standard deviation, median, Q1, Q3, minimum, and 
maximum) by cohortand overall . Plasma concentrations over time will be plotted in 
semilogarithmic and linear formats as mean ± standard deviation and median (Q1, Q3).
To evalua te if the exposu res of LDV and GS -331007achieved in pediatric subjects of this 
study are similar to the exposures observed in adultsubjects(Table9-
1). The LDVand 
GS-331007exposure data from this study  will be compared to the integrated adultdata. The 
primary endpoint of this anal ysis will be evaluated by carrying out an analysis of variance 
(ANOVA) for log- transformed GS-331007 
AUCtauand LDV AUC tau.The secondary  
endpoints of this analy sis will be the Cmaxof LDV and GS-331007 andCtauof LDV. The
90% confidence intervals will be constructed for the ratio of geometric means of each PK 
parameters
. The equivalenc eboundary  is set as 50% to 200%.   
Given that dose ranging studies for SOF established that a dose of 200 mg results in 
suboptimal exposure compared to the 400 mg dose, and the lack of clinically  significant 
exposure-safety relationships observed across a broad range of GS -331007 exposure, bounds 
of 50% to 200% for GS -331007 AUC tauwill allow identification of a clinically relevant 
difference in exposure in the pediatric population.
A phase 2 stud y evaluating LDV doses of 30 or 90 mg LDV in combination with DAAs 
VDV+TGV+RBV suggested L DV exposure may  be suboptimal at the 30 mg dose based on 
the incidence of virologic breakthrough being approxi mately half in the 90 mg arm; as such 
the 90 mg dose was selected for further development.  I n the 90 mg LDV arm of this study , 
the LDV AUC tauat the 25 percentile was 3230 hr*ng/mL.  While this value is 62% lower 
than the mean LDV AUC tau(8530 hr*ng/mL) observed in adult HCV -infected subjects in the 
LDV/SOF FDC Phase 2/3 population, it provides ~99.8% of maximal viral load reduction 
(exposure -response model established in the monotherap y proof of concept study ).  In the 
Phase 2/3 population when administer ed the LDV/SOF FDC, there was a lack of clinically  
significant exposure -efficacy or safety relationships observed across the broad range of LDV 
exposure.  Taken together these data support the utility  of bounds of 50% to 200% for LDV 
AUCtauto identify  a clinically relevant difference in L DV exposure in the pediatric 
population.      
In all pediatric age groups, the targeted exposures for GS -331007 and LDV are the adult 
equivalent for which safety  and efficacy  has been established.  In the absence of any  pediatric 
PK information (ie., variability  and exposure of GS-
331007 or LDV is unknown) assuming a 
2-fold higher  variability , or a 30 % difference in GS -331007 or LDV AUC tauin the pediatric 
population compared to adults, the predicted 90% CIs of the geome tric mean ratio (GMR) 
will be contained within the bounds of 50% to 200%.
Individual patient management will be performed by  maintaining exposures comparable to 
adults.  In the event more than one s
ubject in each cohort exhibits LDV (AUC tau) or 
GS-331007 ( AUCtau) exposures less than the 2.5thpercentile of adult values , a dos
e
assessment may be require for the cohort as appropriate.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page66 10 July2014The effec t of age and LDV/SOF FDC dose on PK (LDV, SOF and GS-331007)willbe 
assessed.
Table9-1. SOF, GS -331007, and LDV PK Parameters a fter Once -Daily 
Administration of SOF/LDV in HCV- Infected Adults 
Subjects 
(Population PK Analysis from Phase 2 and 3 Studies) 
Mean (%CV) PK Param eteraGS-331007 (N=2113) LDV (N=2113)
AUCtau(ng•h/mL) 12,500 (29.2) 8530 (60.8)
Cmax(ng/mL) 736 (28.2) 364 (51.4)
Ctau(ng/mL) N/A 247 (59.2)
a Pharmacokinetic parameters are presented as mean (%CV) and are shown to 3 significant digits.
9.5. Safety Analysis
Safety analysis will be performed for PK Lead-inand overall study  Treatment Phase
respectivel y. Safety data will be summarized by age group, b y GT, by overall and by  age 
group and GT .
Safety will be evaluated by  assessment of clinical laboratory  tests, phy sical examinations, 
vital signs measurements, and by  the documentation of AEs.
All safety data collected while on or after the first dose of study  drug administration up to 
30days after the last dose of study  drug will be summarized by 
cohort according to the study  
drug received.
Safetyendpoints will be anal yzed by the number and percent of subjects with events or 
abnormalities for categorical values or 8 -number summary  (n, mean, standard deviation, 
median, Q1, Q3, minimum, maximum) for continuous data.
9.5.1. Extent of Exposure
A subject’s ex tent of exposure to study  drug will be generated from the study  drug 
administration page of the CRF. Exposure data will be summarized.
9.5.2. Adverse Events
Clinical and laboratory  AEs will be coded using the Medical Dictionary  for Regulatory  
Activities (MedDRA). System Organ Class (SOC), High -Level Group Term (HLGT), 
High-Level Term (HLT), Preferred Term (PT), and L ower-Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A 
treatmen
t-emergent adverse event will be defined as any  new or worsening adverse event that 
begins on or after the date of first dose of stud y drug up to the date of last dose of study drug 
plus 30 day s. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page67 10 July2014Summaries (number and percentage of subjects) of treatm ent-emergent adverse events 
(bySOC and preferred term) will be provided by cohort:
All AEs,
All study drug-related AEs,
Combined Grade 2, 3 and 4 AEs,
Combined Grade 3 and 4 AEs,
Combined Grade 2, 3 and 4 study  drug-related AEs,
Combined Grade 3 and 4 study  drug-related AEs,
All AEs that caused permanent discontinuation from study  drug,
All AEs that caused change in dose or temporary  interruption of study  drug,
All SAEs (including death), and
All study drug-related SAEs
All AEs collected during the course of t he study will be presented in data listings.
9.5.3. Laboratory Evaluations
Selected laboratory  data will be summarized using onl y observed data. Absolute values and 
changes from baseline at all scheduled visits will be summarized .Graded laboratory  
abnormalities will be defined using the grading scheme in Grading of Laboratory  
A
bnormalities provided in Appendix 3. Incidence of treatment -emergent laboratory  
abnormalities, defined as values that increase by 
at least one toxicity  grade from baseline at 
any time post baseline up to and including the date of last dose of study drug plus 30 days, 
will be summarized by  age group and overall . If baseline data are missing, then any  graded 
abnormality  (i.e., at least a Grade 1) will be considered treatment emergent.
All laboratory  abnormalities will be included in the listings of laboratory  data.
9.5.4.
Other Safety Evaluations
9.5.4.1. Tanner Pubertal Stage Assessment
Tanner Stages (Appendix 4)will be summarized by  baseline Tanner Stage using frequency  
and percentage. Age of first menses will be summarized descriptivel y.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page68 10 July20149.5.4.2. Vital Signs (including Body  Weight and Height)
Vital signs including body  weight and height and change from baseline will be summarized 
at each visit b y age group, by GT, b y overall and by age group and GT.
9.6. Efficacy Analysis
Efficacy will be evaluated using scheduled assessments of HCV RNA performed using 
COBAS®TaqMan®HCV Test, v2.0 for use with the High Pure Sy stem.
Efficacy analysis will be performed b y age group, by  GT, by overall, and by  age group and 
GTfor Treatment Phase.
All continuous endpoints will be summarized using an 8 -number summary  (n, mean, 
stand
ard deviation, median, Q1, Q3, minimum, maximum). All categorical endpoints will be 
summarized by  number and percentage of subjects who meet the endpoint definition.
9.6.1. Primary Efficacy Analysis
The primary efficacy endpoint is SVR12 (HCV RNA < LLOQ 12 weeks after completion of 
treatment ) in the FAS population. Point estimate and its 95% confidence interval will be 
provided.  
9.6.2. Secondary 
Efficacy Analysis
For the PK Lead -in Phase, serum HCV RNA actual values and change from baseline will be 
summarized at each v isit.
For the Treatment Phase, the proportion of subjects with HCV RNA below LLOQ over time 
(including SVR endpoints SVR4 and SVR24) will be presented in tabular and graphical 
form. In addition, d escriptive summaries and listings will be provided for addit ional efficacy  
evaluations including serum HCV RNA actual values and change from baseline ,proportion 
of subjects with virologic failures , and other endpoints of interest including AL T 
normalization.
 
 
 
 
9.6.3. S ubgroup Analysis
Subgroup anal ysis on SVR12 will be performed by  treatment experience (treatment -naïve vs. 
treatment 
experienced), by IL28 genot ype, by GT, and by treatment exp erience and GT . 
Other clinicall y relevant subgroup anal yses may be conducted as appropriate (i.e., assuming 
that adequate numbers of subjects in these subsets are available for anal ysis).
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page69 10 July2014Details on efficacy  analyses will be described in the statistical an alysis plan.
9.7. Quality of Life Analysis
The data from PedsQL™ Pediatric Quality  of Lifesurvey will be summarized by  visit and 
age group and overall.
9.8. Data Monitoring Committee
An external multidisciplinary  data monitoring committee (DMC) will review the progress of 
the study and perform interim reviews of safety  and PK data and provide recommendation to 
Gilead about whether the nature, frequency , and severit y of adverse effects associated with 
study treatment warrant the earl y termination of the study in the best interests of the 
participants, whether the study  should continue as planned, or the study  should continue with 
modifications. 
The DMC’s specific activities will be defi ned by a mutually  agreed charter, which will define 
the DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise Gilead regarding future conduct of the study , 
including possible early  study termination, Gilead retains final dec ision-making authorit y on 
all aspects of the stud y.
9.9. Sample Size
With approximately  100 subjects enrolled into each age group of Treatment Phase , a 
two-
sided 95.0% confidence interval of the SVR12 rate will extend at most 5.9% in both 
directions from the observed SVR 12
rate, assuming the expected SVR12 rate is 90%.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page70 10 July201410. RESPONSIBILITIES
10.1. Investigator Responsibilities
10.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of 
the “Declaration of Helsinki ” (as amended in Edinburgh, Tok yo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws 
and regulations of the country  in which the research is conducted, whichever affords the 
greater protectio n to the study  subject. For studies conducted under a United States I ND, the 
investigator will ensure that the basic principles of “Good Clinical Practice,” as outlined in 
21CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, part 50, 
1998, and 21 CFR, part 56, 1998, are adhered to.
Since this is a “covered” clinical trial, the investigator wi ll ensure that 21 CFR, Part 54,
1998, 
is adhered to; a “covered” clinical trial is an y “study of a drug or device in humans submitted 
in a marketing application or reclassification petition subject to this part that the applicant or 
FDA relies on to establish that the product is effective (including studies that show 
equivalence to an effective product) or that make a significant contribution to the 
demonstration of safet y.” This requires that investigators and all subinvestigators must 
provide documentation of their financial interest or arrangements with Gilead Sciences, or 
proprietary  interests in the drug being studied. This documentation m ust be provided before 
participation of the investigator and an y subinvestigator. The investigator and subinvestigator 
agree to notify  Gilead Sciences of any  change to reportable interests during the study  and for 
one year following completion of the study . Study completion is defined as the date that the 
last subject has completed the protocol defined activities.
This study  is also subject to and will be conducted in accordance with 21 CFR, part 320, 
1993, “Retention of Bioavailability  and Bioequivalence T esting Samples.”
10.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Approval
This protocol and an y accompan ying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent /assent) will be submitted by  the investigator to an I RB (for studies 
conducted in the United States) or IEC (for studies conducted outside of the United States). 
Approval from the IRB or IEC must be obtained beforestarting the st udy and should be 
documented in a letter to the investigator specifying the protocol number, protocol version, 
protocol date, documents reviewed, and date on which the committee met and granted the 
approval.
Any modifications made to the protocol after rec eipt of IRB or IEC approval must also be 
submitted to the I RB or IEC for approval before implementation.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page71 10 July201410.1.3. Informed Consent /Assent
The investigator is responsible for obtaining written informed consent from the parent/legal 
guardian of the subject participat ing in this study  after adequate explanation to the 
parent/legal guardian and subject of the aims, methods, objectives, and potential hazards of 
the study and before undertaking any  study-related procedures. Written assent should be 
obtained from the subje ct as required b y IRB/IEC/local requirements for this age population.  
The investigator must utilize an I RB-or IEC-approved consent/assent form for documenting 
written informed consent
/assent. Each informed consent/assent will be appropriatel y signed 
and dated by the subject or the subject’s parent/legally authorized representative and the 
person obtaining consent/assent.
10.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that 
their identities are protecte d from unauthorized parties. Only  subject initials, date of birth, 
and an identification code (i.e., not names) should be recorded on an y form or biological 
sample submitted to the Sponsor, I RB or IEC,or laboratory . The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all 
subjects enrolled in the trial.
The investigator agrees that all information received from Gilead Sciences, including but not 
limited to the I nvestigator Brochure, this protocol, CRFs, the investigational new drug, and 
any other study  information, remain the sole a nd exclusive property of Gilead Sciences 
during the conduct of the study  and thereafter. This information is not to be disclosed to any  
third party  (except employ ees or agents directl y involved in the conduct of the study  or as 
required b y law) without prior written consent from Gilead Sciences. The investigator further 
agrees to take all reasonable precautions to prevent the disclosure by  any employee or agent 
of the study  site to an y third part y or otherwise into the public domain.
10.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the 
study to be full y documented and the study data to be subsequentl y verified. These 
documents should be classified into at least the following two categories: (1) investigator’s 
study file, and (2) subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB or IEC and governmental approval with correspondence, informed consent, drug 
records, staff curriculum vitae and authorization forms, and other appropriate documents and 
correspondence.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page72 10 July2014The required source data are listed in the Source Data verification Plan, and should include 
sequential notes containing at least the following information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, i.e., history , physical exam ination, 
and confirmation of diagnosis (to support inclusion and exclusion criteria);
Participation in trial (including trial number);
Trial discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were p erformed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of trial medication (preferabl y drug 
dispensing and return should be documented as well);
Record of all AEs and other safety parameters (start and end date, and preferabl y 
including causality  and intensity );
Concomitant medication (including start and end date, dose if relevant; dose changes 
should be motivated);
Date of trial completion and reason for earl y discontinuation, if applicable.
All clinical study  documents must be retained b y the investigator until at least 2 years after 
the last approval of a marketing application in an ICH region (i.e., United States, Europe, or 
Japan) and until there are no pending or contemplated marketing applic ations in an I CH 
region; or, if no application is filed or if the application is not approved for such indication, 
until 2years after the investigation is discontinued and regulatory authorities have been 
notified. I nvestigators may  be required to retain documents longer if required by  applicable 
regulatory requirements, by  local regulations, or by  an agreement with Gilead Sciences. The 
investigator must notify
 Gilead Sciences before destroy ing any clinical study  records.
Should the investigator wish to as sign the stud y records to another part y or move them to 
another location, Gilead Sciences must be notified in advance.
If the investigator cannot guarantee this archiving requirement at the study  site for any  or all 
of the documents, special arrangements must be made betw een the investigator and 
GileadSciences to store these in sealed containers outside of the site so that they  can be 
returned sealed to the investigator in case of a regulatory  audit. When source documents are 
required for the continued car e of the subject, appropriate copies should be made for storage 
outside of the site.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page73 10 July2014Biological samples at the conclusion of this study  may be retained in storage by the Sponsor 
for a period up to 1 5years for purposes of this study .
10.1.6. Case Report Forms
For each subject enrolled, a CRF (or eCRF) must be completed and signed by  the principal 
investigator or subinvestigator (as appropriate) within a reasonable time period after data 
collection. This also applies to records for those subjects who f ail to complete the study  
(evenduring a prerandomization screening period if a CRF was initiated). If a subject 
withdraws from the study , the reason must be noted on the CRF. If a subject is withdrawn 
from the study  because of a treatment -limiting adverse event, thorou gh efforts should be 
made to clearly  document the outcome.
10.1.7.
Drug Accountability
The investigator or designee (i.e., pharmacist) is responsible for ensuring adequate 
accountability  of all used and unused investigational medicinal product, and comparators. 
This includes acknowledgment of receipt of each shipment of study  product (quantity  and 
condition), subject dispensing records, and returned or destro yed study product. Dispensing 
records will document quantities received from Gilead Sciences and quantities dispensed to 
subjects, including lot number, date dispensed, subject identifier number, subject initials, and 
the initials of the person dispensing the medication.
At study initiation, the monitor will evaluate the site’s standard operating procedure for 
investigational medicinal product disposal/destruction in order to ensure that it complies with 
Gilead Sciences requirements. Drug may  be returned or destro yed on an ongoing basis during 
the study if appropriate. At the end of the stud y, following final dru g inventory  reconciliation 
by the monitor, the study site will dispose of and/or destroy  all unused investigational 
medicinal product supplies, including empty containers, according to these procedures. If the 
site cannot meet Gilead Sciences’ requirementsfor disposal, arrangements will be made 
between the site and Gilead Sciences or its representative for destruction or return of unused 
investigational medicinal product supplies.
All drug supplies and associated documentation will be periodically  reviewed and verified b y 
the study monitor over the course of the study .
10.1.8. Inspections
The investigator should understand that source documents for this trial should be made 
available to appropriatel y qualified personnel from Gilead Sciences or its representatives, to 
IRBs or IECs, or to regulatory  authority or health authority inspectors.
10.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page74 10 July201410.2. Sponsor Responsibilities
10.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, 
may be made onl y by Gilead Sciences. All protocol modifications must be submitted to the 
IRB or IEC in accordance with local r equirements. Approval must be obtained before 
changes can be implemented.
10.2.2. Study Report and Publications
A clinical study  report will be prepared and provided to the regulatory  agency(ies). 
GileadSciences will ensure that the report meets the standards set out in the I CH Guideline 
for Structure and Content of Clinical Study  Reports (I CHE3). Note that an abbreviated 
report may  be prepared in certain cases.
After conclusion of the study  and without prior written approval from Gilead Sciences, 
investigators in this study may  communicate, orally  present, or publish in scientific journals 
or other scholarly  media only after the following conditions have been met
:
the results of the study in their entiret y have been publicly disclosed b y or with the 
consent of Gilead Sciences in an abstract, manuscript, or presentation form; or
the study has been completed at all study sites for at least 2 years.
No such communica tion, presentation, or publication will include Gilead Sciences’ 
confidential information (see Section10.1.4).
The investigator will submit any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at leas t 30days before submission of the 
publication or presentation. The investigator will comply  with Gilead Sciences’ request to 
delete references to its confidential information (other than the stud y results) in any paper or 
presentation and agrees to withhold publication or presentation for an additional 60 days in 
order to obtain patent protection if deemed necessary .
10.3. Joint Investigator/Sponsor Responsibilities
10.3.1. Access to Information for Monitoring
In accordance with ICH Good Clinical Practice (ICH GCP) guid elines, the study  monitor 
must have direct access to the investigator’s source documentation in order to verify  the data 
recorded in the CRFs for consistency .
The monitor is responsible for routine review of the CRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records 
needed to verify  the entries on the CRFs. The investigator agrees to cooperate w ith the 
monitor to ensure that any  problems detected in the course of these monitoring visits are 
resolved.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page75 10 July201410.3.2. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead Sciences may  conduct inspections or 
audits of the clinical study. If the investigator is notified of an inspection by a regulatory  
authority the investigator agrees to notify the Gilead Sciences medical monitor immediately . 
The investigator agrees to provide to representatives of a regulatory  agency or 
GileadSciences access to records, facilities, and personnel for the effective conduct of any  
inspection or audit.
10.3.3. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. 
Should this be necessa ry, both parties will arrange discontinuation procedures and notify  the 
appropriate regulatory  authority (ies), IRBs, and IECs. In terminating the study , 
GileadSciences and the investigator will assure that adequate consideration is given to the 
protection of the subjects’ interests.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page76 10 July201411. REFERENCES
19705 Esteban J I, Sauleda S, Quer J. The changing epidemiology  of hepatitis C virus 
infection in Europe. J Hepatol 2008;48 (1):148-62.
19799 Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis 
C in children: a sy stematic review. PLoS ONE 2010;5 (7):e11542.
19801 Mohan N, Gonzalez -Peralta RP, Fujisawa T, Chang MH, Heller S, Jara P, et 
al. Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr 
2010;50 
(2):123-31.
20273 Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. 
Long-term course of chronic hepatitis C in children: from viral clearance to 
end-stage liver disease. Gastroenterology  2008;134 (7):1900-7.
20282 Serranti D, Buonse nso D, Ceccarelli M, Gargiullo L , Ranno O, Valentini P. 
Pediatric hepatitis C infection: to treat or not to treat...what's the best for the 
child? European review for medical and pharmacological sciences 2011;15 
(9):1057-67.
20285 Wirth S. Current treatment options and response rates in children with chronic 
hepatitis C. World J Gastroenterol 2012;18 (2):99 -104.
20286 Wirth S, Ribes -Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et 
al. High sustained virologic response rates in children with chroni c hepatitis C 
receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52 (4):501- 7.
28583 Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. L edipasvir 
and sofosbuvir for untreated HCV genot ype 1 infection. N Engl J Med 
2014;370 (20):1 889-98.
28585 Afdhal N, Redd y KR, Nelson DR, L awitz E, Gordon SC, Schiff E, et al. 
Ledipasvir and sofosbuvir for previously  treated HCV genot ype 1 infection. N 
Engl J Med 2014;370 (16):1483 -93.
28587 Kowdley KV, Gordon SC, Reddy  KR, Rossaro L, Bernstein DE, Lawitz E, et 
al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without 
cirrhosis. N Engl J Med 2014;370 (20):1879
-88.
29292 Gane E, Hy land RH, An D, Pang PS, Sy monds WT, McHutchison JG, et al. 
Ledipasvir/Sofosbuvir Fixed -Dose Combination Is Safe and Effective in 
Difficult-to-Treat Populations I ncluding GT 3 Patients, Decompensated GT 1 
Patients, and GT 1 Patients With Prior Sofosbuvir Experience [Oral 
Presentation 6]. 49th Annual Meeting of The European Association for the 
Study of the Liver (EASL); 2014 April 9- 13; London, UK. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page77 10 July201412. APPENDICES
Appendix 1.Investigator Signature Page
Appendix 2.Study Procedures Table
Appendix 3.GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities
Appendix 4.Tanner Stages
Appendix 5.Pregnancy Precautions, Definiti on for Female of Childbearing Potential, and 
Contraceptive Requirements
PPDLDV/SOFFDC 
Protocol GS-US-337-1116 Final 
Gilead Sciences, Inc. Original 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 2, Open-Label, Multicenter, Muti-cohort Study to Investigate the Safety and 
Efficacy of Ledipasvir/Sofosbuvir in Adolescents and Children with Chronic HCV­
infection 
GS-US-337-1116, Original Protocol, 10 July 2014 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
Luisa Stamm, MD, PhD (Printed) 
Medical Monitor 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to 
all information provided by Gilead Sciences, Inc. I will discuss this material with them to 
ensure that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDENTIAL Page 78 10 July 2014 
Sofosbuvir
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page79 10 July2014Appendix 2. Study Procedures Table
Table1. PK Lead -in: Screening and On -Treatment Study Visits
Screening
(-28 days)On-treatment
Day1bDay 3Day 10
(+ 3 days)
Clinical Assessments
Informed Consent / Assent X
Determine Eligibility X X
Medical History Xj
Complete Physical Examination X X
Symptom -directed Physical Examination X X
Tanner Pubertal Stage Assessment X
Vital SignsaX X X X
Bone Age Assessment X
AEs and Concomitant Medications X X X X
Pregnancy Prevention CounselingfX
LDV/SOF FDC Swallowability Assessment X Xh
Quality of Life Survey Xi
Review of Study 
Medication ComplianceX X
Study Drug DispensingbX
Subject Dosing Diary X X X
Laboratory Assessments
Hematology, Chemistry X X X X
Coagulation Tests X X X
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page80 10 July 2014Screening
(-28 days)On-treatment
Day1bDay 3Day 10
(+ 3 days)
HCV RNA X X X X
Viral Sequencing cX X X
Serum or Urine Pregnancy TestingeX X X
Urinalysis X X X
Urine Drug Screen X
Intensive PK X d
HCV Genotyping, IL28B X
HCV antibody, HIV 1/2 antibody, HBs 
antigen, HAV antibodyX
HbA1c X
TSH X
Alpha fetoprotein X
Alpha-1 anti-trypsin X
a Vital signs include blood pressure, pulse, respiratory rate and temperature, body weight, and height
bDay 1 assessments must be performed prior to dosing
cPlasma samples will be collected and stored for potential HCV sequencing and other virology studies
d For Cohorts 1 and 2, plasma samples will be collected for PK analyses following dosing of study drugs on Day 10at the following time points: 0 (predose), 0.5, 1, 2, 3, 4, 5,
8, and 12 hours post -dose. For Cohort 3, plasma samples for PK analyses will be collected at the following time points: 0 (predose), 0.5, 2, 4, 8, and 12 hours post-dose.
e Females of childbearing potential only. Serum pregnancy test performed at screening and for confirmation of po sitive urine pregnancy test. 
fIncluding partner pregnancy prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of the Investigator based on 
subject’s pubertal status ). 
g
hSwallowability can occur at Day 1 if not completed during screening.
iQuality of life survey will be completed by all subje cts if a site is approved to use the survey. Subject is to review questionnaire with a parent/guardian and write/mark 
answers directly onto the questionnaire.
jParental height will be collected with medical history at Screening (if available) as stated in S ection6.2.1
PPD
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page81 10 July 2014Table2. Treatment Phase : Screening and On -Treatment Study Visits
Screeningc
(-28 days) Day1cVisit identified by on -treatment study week
1c2 4 8 12Early 
Termination
Clinical Assessments
Informed Consent / Assent X
Determine Eligibility X X
Medical History Xi
Complete Physical Examination X X X X
Symptom -Directed Physical Examination X X X X
Tanner Pubertal Stage Assessment X X X
Vital SignsaX X X X X X X X
Bone Age Assessment X
AEs and Concomitant Medications X X X X X X X X
Pregnancy Prevention Counseling gX X X
LDV/SOF FDC Swallowability Assessment X Xh
Quality of Life Survey eX X X
Review of Study Medication Compliance X X X X
Study Drug Dispensingb
X X X
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page82 10 July 2014Screeningc
(-28 days) Day1cVisit identified by on -treatment study week
1c2 4 8 12Early 
Termination
Laboratory Assessments
Hematology, Chemistry, Coagulation X X X X X X X X
HCV RNA X X X X X X X X
Viral Sequencing dX X X X X X X
Serum or Urine Pregnancy Testing X X X X X X
Single PK X X X X X X
Urinalysis X X
Urine Drug Test X
HCV Genotyping, IL28B X
HCV antibody, HIV 1/2 antibody, HBs antigen, 
HAV antibodyX
HbA1c X
TSH X X X
Alpha fetoprotein, Alpha -1 anti-trypsin X
a Vital signs include blood pressure, pulse, respiratory rate and temperature, and body weight and height
b The IWRS will provide direction on the specifics of each subject’s study drug dispensing.
c Subjects rolling over from PK Lead-in will not be required to repeat screening, Day 1 or Week 1 visits during the on Treatment Phase  
d Plasma samples will be collected and stored for potential HCV sequencing and other virology studies
eQuality of life survey will be completed at Day 1, Week 12 ,and Early Termination i f a site is approved to use the survey. Subject is to review questionnaire witha 
parent/guardian and write/mark answers directly onto the questionnaire .
f
gIncluding partner pregnancy prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of the Investigator based on 
subject’s pubertal status ).
hSwallowability can occur at Day 1 if not completed during screening.
iParental height will be collected with medical history at Screening (if available) as stated in Section 6.2.1
PPD
PPD
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page83 10 July 2014Table3. Treatment Phase : Post Treatment Visits Following Primary Study
4 Weeks Post Treatm ent 12 Weeks Post Treatment 24 Weeks Post Treatment
Clinical Assessments
Vital Signs, Body weight and Height X X X
Symptom -directed Physical Exam X X X
AEs X XcXc
Concomitant Medications X
Quality of Life SurveyaX X
Tanner Pubertal Stage Assessment X X
Bone Age Assessment X
Pregnancy Prevention CounselingdX X
Laboratory Assessments
Hematology, Chemistry X X
HCV RNA X X X
Viral Sequencing bX X X
Urine Pregnancy Test X X
a Quality of life survey will be completed by all subjects at 12-Week and 24 -Week Post Treatment visits if a site is approved to use the survey.  Subject is to review 
questionnaire with a parent/guardian and write/mark answers directly onto the questionnaire .
b Plasma samples will be collected and stored for potential HCV sequencing and other virology studies
cAt Post Treatment Week 12 and 24, only SAEs will be captured
dIncluding partner pregnancy prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of the Investigator based on 
subject’s pubertal status ).
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page84 10 July 2014Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Version: 18June2012
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Anydecrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 7Days1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page85 10 July 2014HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Infant, 2 –7 Days 1250 to 1500/mm3
1.25to1.50 GI/L1000 to 1250/mm3
1.00to< 1.25 GI/L750 to 1000/mm3
0.75to< 1.00 GI/L750/mm3
< 0.75 GI/L
Infant, 1 Day 4000 to 5000/mm3
4.00to5.00 GI/L3000 to 4000/mm3
3.00to < 4.00 GI/L1500 to 3000/mm3
1.50to< 3.00 GI/L1500/mm3
< 1.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page86 10 July 2014HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperfibrinogenemia ULN to 600mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0% 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page87 10 July 2014CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia 146  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
146  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 3.0 to3.4 mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to3.4 mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Hyperkalemia 5.6 to 6.0 mEq/L 6.0 to 6.5 mEq/L 6.5 to 7.0 mEq/L 7.0 mEq/L
5.6 to 6.0 mmol/L 6.0 to 6.5 mmol/L 6.5 to 7.0 mmol/L 7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL 40 to55mg/dL 30 to40mg/dL 30 mg/dL
3.03 to 3.58 mmol/L 2.20 to3.03mmol/L 1.64 to2.20mmol/L 1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page88 10 July 2014CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
7Days7.8 to 8.4  mg/dL 7.0 to7.8 mg/dL 6.1 to7.0mg/dL 6.1mg/dL
1.94 to 2.10 mmol/L 1.74 to1.94 mmol/L 1.51 to1.74 mmol/L 1.51mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38 mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL 1.5 to 2.0 mg/dL 1.0 to 1.5 mg/dL 1.0 mg/dL
0.63  to LLN mmol/L 0.47 to 0.63 mmol/L 0.31 to 0.47 mmol/L 0.31 mmol/L
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page89 10 July 2014CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric 1 Year– 14 Years 3.0 to 3.5 mg/dL
0.96 to 1.14 mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to 4.5 mg/dL
1.12 to 1.46 mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia 1.5 mg/dL to LLN 1.0 to1.5 mg/dL 0.5 to1.0 mg/dL 0.5 mg/dL
87 μmol/L to LLN 57 to87 μmol/L 27 to57 μmol/L 27 μmol/L
Creatinine 1.50 to 2.00 mg/dL 2.00 to 3.00 mg/dL 3.00 to 6.00 mg/dL 6.00 mg/dL
133 to 177 μmol/L 177 to 265 μmol/L 265 to 530 μmol/L 530 μmol/L
Bicarbonate 16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page90 10 July 2014CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Triglycerides
(Fasting)NA 500 to 750 mg/dL 750 to 1200 mg/dL 1200 mg/dL
5.64–8.47 mmol/L 8.47–13.55 mmol/L 13.55 mmol/L
LDL
(Fasting)130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
Pediatric >2 to <18 years 110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
*Calcium should be corrected for albumin if albumin is < 4.0 g/dL
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page91 10 July 2014ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin 3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page92 10 July 2014URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to1999 mg/24 h >1999to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499to799 mg/m2/24 h >799to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratorie s, toxicity grades will only be assigned to Dipstick 
Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for the 
AE.
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page93 10 July 2014CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secComplete AV block 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page94 10 July 2014CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, p ulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page95 10 July 2014RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page96 10 July 2014SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerComplete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing i nability to 
perform usual social & 
functional activities NA
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page97 10 July 2014GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page98 10 July 2014GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vomiting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(eg, hypotensive shock)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page99 10 July 2014NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than mi nimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usua l 
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inabilit y to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page100 10 July 2014NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page101 10 July 2014NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page102 10 July 2014MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page103 10 July 2014SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalizat ion (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or tot al parenteral 
nutrition]
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page104 10 July 2014INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual
social & functional activitiesPain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page105 10 July 2014ENDOCRINE/METABOLIC
Grade1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities , 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page106 10 July 2014GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHemorrhage with life -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic an tiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page107 10 July 2014Appendix 4. Tanner Stages
1. Pubic hair (male and female)
Tanner I no pubic hair at all ( prepubertal Dominic state)
Tanner II small amount of long, dow ny hair with slight pigmentation at the base of the penisand scrotum(males) or on the labia majora (females)
Tanner III hair becomes more coarse and curly, and begins to extend laterally
Tanner IV adult-like hair quality, extending across pubis but sparing medial thighs
Tanner V hair extends to medial surface of the thighs
2. Genitals (m ale) (One standard deviation around m ean age)
Tanner I Testes, scrotum, and penis about same size and proportion as in early childhood
Tanner II Enlargement of scrotum and testes; skin of scrotum reddens and changes in texture; little or no enlargement of penis (10.5 -12.5)
Tanner III Enlargement of penis, first mainly in length; further growth of testes and scrotum (11.5 -14)
Tanner IV Increased size of penis with grow th in breadth and development of glans; further enlargement of testes and scrotum and increa sed darkening 
of scrotal skin (13.5 -15)
Tanner V Genitalia adult in size and shape
3. Breasts (fem ale)
Tanner I no glandular tissue: areolafollows the skin contours of the chest
Tanner II breast bud forms, with small area of surrounding glandular tissue; areola begins to widen 
Tanner III breast begins to become more elevated, and extends beyond the borders of the areola, w hich continues to widen but remains in contour with 
surrounding breast 
Tanner IV increased breast size and elevation; areola and papillaform a secondary mound projecting from the contour of the surrounding breast
Tanner V breast reaches final adult size; areola returns to contour of the surrounding breast, w ith a projecting central papilla. 
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page108 10 July 2014Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1.Background
Non-clinical toxicity  studies of LDV/SOF FDC demonstrated no adverse effect on fertility  or 
embryo-fetal development. However, there are no clinical studies of LDV/SOF FDC in 
pregnant women. Please refer to the latest version of the investigator’s brochure for 
additional information
.
2.Definition of Female of Childbearing Potential and Contraceptive Requireme nts for 
Female Subjects (and their male partners)
For the purpose of this trial, all post -menarchal females will be considered to be of 
childbearing potential, unless there is documentation of irreversible ovarian failure or 
surgical sterilization.
Post-menarchal females must have a negative serum pregnancy  test at Screening and a 
negative urine pregnancy test on the Day  1 visit prior to randomization. They  must also agree 
to one of the following from 3 weeks prior to Day 1 until 30 days after last dose of LDV/SOF 
FDC:
Complete abstinence from intercourse. Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post- ovulation methods) is not permitted.
Or
Consistent and correct use of 1 of the following methods of birth control listed below, in 
addition to a male partner who correctly uses a condom, from the date of Screening until 
30 days  after the last dose of LDV/SOF FDC :
— intrauterine device (IUD) with a failure rate of < 1% per year
— female barrier method: cervical cap or diaphragm with spermicidal agent
—tubal sterilization
—vasectomy in male partner
— implants of levonorgestrel
—injectable progesterone
—oral contraceptives (either combined or progesterone only )
—contraceptive vaginal ring 
—transdermal contraceptive patch
LDV/SOF FDC
Protocol GS -US-337-1116 Final
Gilead Sciences, Inc Original
CONFIDENTIAL Page109 10 July 20143.Contraceptive Requirements for Ma le Subjects (and their female partners)
All male study  participants must agree to consistently  and correctly  use a condom from 
Day1until 90 daysafter the last dose of LDV/SOF FDC . If their female partner is of 
childbearing potential (as defined above), their female partner must use 1 of the methods of 
birth control listed above from the date of Screening until 90 daysafter last dose of 
LDV/SOF FDC .
Male subjects must agree to refrain from sperm donation for at least 90 daysafter the last 
dose of LDV/SOF FDC .
4. Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time 
during the stud y, or if they become pregnant within 90 daysof last LDV/SOF FDC dose.
Subjects who become pregnant or who suspect that they are pregnant must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose 
partner has become pregnant or suspects she is pregnant must report the information to the 
investigator. 
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined 
in Section8.5.2.1.